<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antithrombotic treatment after stroke due to intracerebral haemorrhage - Cochrane, A - 2023 | Cochrane Library</title> <meta content="Antithrombotic treatment after stroke due to intracerebral haemorrhage - Cochrane, A - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012144.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antithrombotic treatment after stroke due to intracerebral haemorrhage - Cochrane, A - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012144.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012144.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Antithrombotic treatment after stroke due to intracerebral haemorrhage" name="citation_title"/> <meta content="Alexia Cochrane" name="citation_author"/> <meta content="The University of Edinburgh" name="citation_author_institution"/> <meta content="Chen Chen" name="citation_author"/> <meta content="Jacqueline Stephen" name="citation_author"/> <meta content="The University of Edinburgh" name="citation_author_institution"/> <meta content="Ole Morten RÃ¸nning" name="citation_author"/> <meta content="Akershus University Hospital" name="citation_author_institution"/> <meta content="Craig S Anderson" name="citation_author"/> <meta content="Graeme J Hankey" name="citation_author"/> <meta content="Rustam Al-Shahi Salman" name="citation_author"/> <meta content="The University of Edinburgh" name="citation_author_institution"/> <meta content="rustam.al-shahi@ed.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD012144.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/01/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012144.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012144.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012144.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [adverse effects]; *Atrial Fibrillation; Cerebral Hemorrhage; Fibrinolytic Agents [adverse effects]; Platelet Aggregation Inhibitors [adverse effects]; *Stroke [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012144.pub3&amp;doi=10.1002/14651858.CD012144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="VXKc2U6b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012144\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012144\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ko","th","ms","ja","hr","id","fa","fr","pl","ro"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD012144.pub3",title:"Antithrombotic treatment after stroke due to intracerebral haemorrhage",firstPublishedDate:"Jan 26, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012144.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012144.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> EspaÃ±ol </option> <option class="content-language-option" data-languagecode="fa" value="fa"> ÙØ§Ø±Ø³Û </option> <option class="content-language-option" data-languagecode="fr" value="fr"> FranÃ§ais </option> <option class="content-language-option" data-languagecode="hi" value="hi"> à¤¹à¤¿à¤¨à¥à¤¦à¥ </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> æ¥æ¬èª </option> <option class="content-language-option" data-languagecode="ko" value="ko"> íêµ­ì´ </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> PortuguÃªs </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Ð ÑÑÑÐºÐ¸Ð¹ </option> <option class="content-language-option" data-languagecode="ro" value="ro"> RomÃ¢nÄ </option> <option class="content-language-option" data-languagecode="ta" value="ta"> à®¤à®®à®¿à®´à¯ </option> <option class="content-language-option" data-languagecode="th" value="th"> à¸ à¸²à¸©à¸²à¹à¸à¸¢ </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> ç¹é«ä¸­æ </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> ç®ä½ä¸­æ </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012144.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012144.pub3/full/es"> EspaÃ±ol </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012144.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012144.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;ÚÚ©ÛØ¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;ì´ë¡&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;à¸à¸à¸à¸±à¸à¸¢à¹à¸­&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en tÃ©rminos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Ø®ÙØ§ØµÙ Ø¨Ù Ø²Ø¨Ø§Ù Ø³Ø§Ø¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© simplifiÃ©&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;LaiÄki saÅ¾etak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;ä¸è¬èªè¨³&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;ì¬ì´ ë§ ìì½&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym jÄzykiem&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;à¸à¹à¹à¸­à¸ªà¸£à¸¸à¸à¸ à¸²à¸©à¸²à¸à¸£à¸£à¸¡à¸à¸²&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;æ·ºé¡¯ææçå£èªçµè«&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012144.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012144.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012144.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012144.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views:Â </span> <span>7992 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012144.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-sec-0080"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-sec-0070"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/appendices#CD012144-sec-0085"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/supinfo/CD012144StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/supinfo/CD012144StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright Â© 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antithrombotic treatment after stroke due to intracerebral haemorrhage</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/information#CD012144-cr-0004">Alexia Cochrane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/information#CD012144-cr-0005">Chen Chen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/information#CD012144-cr-0006">Jacqueline Stephen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/information#CD012144-cr-0007">Ole Morten RÃ¸nning</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/information#CD012144-cr-0008">Craig S Anderson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/information#CD012144-cr-0009">Graeme J Hankey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012144.pub3/information#CD012144-cr-0010"><i class="icon corresponding-author fa fa-envelope"></i>Rustam Al-Shahi Salman</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/information/en#CD012144-sec-0093">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 January 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012144.pub3">https://doi.org/10.1002/14651858.CD012144.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012144-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012144-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012144-abs-0018">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012144-abs-0012">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012144-abs-0014">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012144-abs-0004">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="full/th#CD012144-abs-0006">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012144-abs-0001" lang="en"> <section id="CD012144-sec-0001"> <h3 class="title" id="CD012144-sec-0001">Background</h3> <p>This is an update of the Cochrane Review last published in 2017. Survivors of stroke due to intracerebral haemorrhage (ICH) are at risk of major adverse cardiovascular events (MACE). Antithrombotic (antiplatelet or anticoagulant) treatments may lower the risk of ischaemic MACE after ICH, but they may increase the risk of bleeding. </p> </section> <section id="CD012144-sec-0002"> <h3 class="title" id="CD012144-sec-0002">Objectives</h3> <p>To determine the overall effectiveness and safety of antithrombotic drugs on MACE and its components for people with ICH. </p> </section> <section id="CD012144-sec-0003"> <h3 class="title" id="CD012144-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group Trials Register (5 October 2021). We also searched the Cochrane Central Register of Controlled Trials (CENTRAL: the Cochrane Library 2021, Issue 10), MEDLINE Ovid (from 1948 to October 2021) and Embase Ovid (from 1980 to October 2021). The online registries of clinical trials searched were the US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (5 October 2021). We screened the reference lists of included randomised controlled trials (RCTs) for additional, potentially relevant RCTs. </p> </section> <section id="CD012144-sec-0004"> <h3 class="title" id="CD012144-sec-0004">Selection criteria</h3> <p>We selected RCTs in which participants with ICH of any age were allocated to a class of antithrombotic treatment as intervention or comparator. </p> </section> <section id="CD012144-sec-0005"> <h3 class="title" id="CD012144-sec-0005">Data collection and analysis</h3> <p>In accordance with standard methodological procedures recommended by Cochrane, two review authors assessed each selected RCT for its risk of bias and extracted data independently. The primary outcome was a composite of MACE, and secondary outcomes included death, individual components of the MACE composite, ICH growth, functional status and cognitive status. We estimated effects using the frequency of outcomes that occurred during the entire duration of followâup and calculated a risk ratio (RR) for each RCT. We grouped RCTs separately for analysis according to 1) the class(es) of antithrombotic treatment used for the intervention and comparator, and 2) the duration of antithrombotic treatment use (short term versus long term). We pooled the intentionâtoâtreat populations of RCTs using a fixedâeffect model for metaâanalysis, but used a randomâeffects model if RCTs differed substantially in their design or there was considerable heterogeneity (I<sup>2</sup> â¥ 75%) in their results. We applied GRADE to assess the certainty of the evidence. </p> </section> <section id="CD012144-sec-0006"> <h3 class="title" id="CD012144-sec-0006">Main results</h3> <p>We identified seven new completed RCTs for this update, resulting in the inclusion of a total of nine RCTs based in secondary care, comprising 1491 participants (average age ranged from 61 to 79 years and the proportion of men ranged from 44% to 67%). The proportion of included RCTs at low risk of bias, by category was: random sequence generation (67%), allocation concealment (67%), performance (22%), detection (78%), attrition (89%), and reporting (78%). </p> <p>For starting versus avoiding shortâterm prophylactic dose anticoagulation after ICH, no RCT reported MACE. The evidence is very uncertain about the effect of starting shortâterm prophylactic dose anticoagulation on death (RR 1.00, 95% CI 0.59 to 1.70, P = 1.00; 3 RCTs; very lowâcertainty evidence), venous thromboembolism (RR 0.84, 95% CI 0.51 to 1.37, P = 0.49; 4 RCTs; very lowâcertainty evidence), ICH (RR 0.24, 95% CI 0.04 to 1.38, P = 0.11; 2 RCTs; very lowâcertainty evidence), and independent functional status (RR 2.03, 95% CI 0.78 to 5.25, P = 0.15; 1 RCT; very lowâcertainty evidence) over 90 days. </p> <p>For starting versus avoiding longâterm therapeutic dose oral anticoagulation for atrial fibrillation after ICH, starting longâterm therapeutic dose oral anticoagulation probably reduces MACE (RR 0.61, 95% CI 0.40 to 0.94, P = 0.02; 3 RCTs; moderateâcertainty evidence) and probably reduces all major occlusive vascular events (RR 0.27, 95% CI 0.14 to 0.53, P = 0.0002; 3 RCTs; moderateâcertainty evidence), but probably results in little to no difference in death (RR 1.05, 95% CI 0.62 to 1.78, P = 0.86; 3 RCTs; moderateâcertainty evidence), probably increases intracranial haemorrhage (RR 2.43, 95% CI 0.88 to 6.73, P = 0.09; 3 RCTs; moderateâcertainty evidence), and may result in little to no difference in independent functional status (RR 0.98, 95% CI 0.78 to 1.24, P = 0.87; 2 RCTs; lowâcertainty evidence) over one to three years. </p> <p>For starting versus avoiding longâterm antiplatelet therapy after ICH, the evidence is uncertain about the effects of starting longâterm antiplatelet therapy on MACE (RR 0.89, 95% CI 0.64 to 1.22, P = 0.46; 1 RCT; moderateâcertainty evidence), death (RR 1.08, 95% CI 0.76 to 1.53, P = 0.66; 1 RCT; moderateâcertainty evidence), all major occlusive vascular events (RR 1.03, 95% CI 0.68 to 1.55, P = 0.90; 1 RCT; moderateâcertainty evidence), ICH (RR 0.52, 95% CI 0.27 to 1.03, P = 0.06; 1 RCT; moderateâcertainty evidence) and independent functional status (RR 0.95, 95% CI 0.77 to 1.18, P = 0.67; 1 RCT; moderateâcertainty evidence) over a median followâup of two years. </p> <p>For adults within 180 days of nonâcardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior ICH, there was no evidence of an effect of longâterm cilostazol compared to aspirin on MACE (RR 1.33, 95% CI 0.74 to 2.40, P = 0.34; subgroup of 1 RCT; lowâcertainty evidence), death (RR 1.65, 95% CI 0.55 to 4.91, P = 0.37; subgroup of 1 RCT; lowâcertainty evidence), or ICH (RR 1.29, 95% CI 0.35 to 4.69, P = 0.70; subgroup of 1 RCT; lowâcertainty evidence) over a median followâup of 1.8 years; all major occlusive vascular events and functional status were not reported. </p> </section> <section id="CD012144-sec-0007"> <h3 class="title" id="CD012144-sec-0007">Authors' conclusions</h3> <p>We did not identify beneficial or hazardous effects of shortâterm prophylactic dose parenteral anticoagulation and longâterm oral antiplatelet therapy after ICH on important outcomes. Although there was a significant reduction in MACE and all major occlusive vascular events after longâterm treatment with therapeutic dose oral anticoagulation for atrial fibrillation after ICH, the pooled estimates were imprecise, the certainty of evidence was only moderate, and effects on other important outcomes were uncertain. Large RCTs with a low risk of bias are required to resolve the ongoing dilemmas about antithrombotic treatment after ICH. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012144-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012144-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012144-abs-0019">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012144-abs-0013">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012144-abs-0015">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012144-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD012144-abs-0011">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012144-abs-0009">æ¥æ¬èª</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012144-abs-0005">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012144-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012144-abs-0016">Polski</a> </li> <li class="section-language"> <a class="" href="full/ro#CD012144-abs-0017">RomÃ¢nÄ</a> </li> <li class="section-language"> <a class="" href="full/th#CD012144-abs-0007">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012144-abs-0003">ç¹é«ä¸­æ</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012144-abs-0002" lang="en"> <h3>Drugs to prevent clots after bleeding in the brain</h3> <p><b>Review question</b><br/>What are the benefits and risks of drugs used to prevent clots (known as 'antithrombotic drugs') in the short term and long term after a stroke due to bleeding in the brain (known as 'brain haemorrhage')? </p> <p><b>Background</b><br/>People with stroke due to brain haemorrhage are more likely to develop clots in their blood vessels than people without brain haemorrhage. Immobility early after the stroke can cause clots in the veins of the legs and pelvis. Patients' underlying medical conditions in both the short and long term after the stroke can also cause clots in the arteries of the lungs, brain, heart, legs or other organs. These clots can cause serious illness or death. Antithrombotic drugs can prevent clots. However, these drugs can also lead to bleeding problems, which can cause serious illness or death. Whether antithrombotic drugs benefit or harm patients after brain haemorrhage is unknown. This is an update of a Cochrane Review, which was last published in 2017. </p> <p><b>Study characteristics</b><br/>We updated our extensive searches for randomised controlled trials, which are the fairest tests of treatment, in October 2021. We found nine trials, which included 1491 people with a brain haemorrhage in the past. Four trials studied shortâterm use of injected blood thinning drugs (known as 'anticoagulants') in immobile brain haemorrhage survivors. Three trials studied longâterm use of oral anticoagulants in brain haemorrhage survivors with an irregular heart beat (known as 'atrial fibrillation'). One trial studied longâterm use of oral blood thinning drugs (known as 'antiplatelet drugs') after brain haemorrhage, and another trial compared two different types of antiplatelet drug. </p> <p><b>Key results</b><br/>We did not identify significant benefits or risks of shortâterm injected anticoagulants or longâterm oral antiplatelet drugs. Although longâterm oral anticoagulants reduced the risk of any major bleeding or clotting event in brain haemorrhage survivors with atrial fibrillation, the findings were not precise, and we were only moderately certain about the evidence. We did not identify significant differences in benefits or risks when comparing two longâterm antiplatelet drugs (cilostazol versus aspirin) for people who had both a stroke or miniâstroke due to clotting and a brain haemorrhage in the past. </p> <p><b>Conclusion</b><br/>Although antithrombotic drugs appear to be promising after brain haemorrhage, we cannot be certain on the basis of the trials that have been done so far. Larger trials are needed to be sure about the effects of these drugs after brain haemorrhage. Eight ongoing trials will help resolve these uncertainties if they recruit large numbers of participants. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012144-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012144-sec-0080"></div> <h3 class="title" id="CD012144-sec-0081">Implications for practice</h3> <section id="CD012144-sec-0081"> <p>On the basis of the available evidence, we could not be certain about benefit or harm from antithrombotic treatment after intracerebral haemorrhage (ICH). </p> <p>We did not identify beneficial or hazardous effects of shortâterm prophylactic dose parenteral anticoagulation on our primary or secondary outcomes, so there are no implications for clinical practice. </p> <p>The reduction of major adverse cardiovascular events (MACE) overall and ischaemic stroke by longâterm treatment with therapeutic dose oral anticoagulation for atrial fibrillation (AF) after intracerebral haemorrhage (ICH) provides some reassurance for the use of this treatment (<a href="./references#CD012144-fig-0011" title="">Analysis 2.1</a>). However, the pooled estimate was imprecise, none of the individual randomised controlled trials (RCTs) were conclusive, there was some heterogeneity between the RCTs, and we were only moderately certain about the evidence, and the possibility of an increase in recurrent ICH remains, so we cannot identify specific implications for clinical practice. Clinical guidelines that are being updated following the publication of these RCTs are yet to publish their recommendations for clinical practice (<a href="./references#CD012144-bbs2-0030" title="Hemphill JC 3rd, GreenbergSM , AndersonCS , BeckerK , BendokBR , CushmanM , et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2015;46:2032-60. [DOI: 10.1161/STR.0000000000000069]">AHA ICH guideline 2015</a>;Â <a href="./references#CD012144-bbs2-0043" title="SteinerT , Al-Shahi SalmanR , BeerR , ChristensenH , Cordonnier, CsibaL , et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. International Journal of Stroke2014;9:840-55. [DOI: 10.1111/ijs.12309]">ESO ICH Guideline 2014</a>;Â <a href="./references#CD012144-bbs2-0053" title="Intercollegiate Stroke Working Party. Royal College of Physicians. 5th edition. London, UK: Royal College of Physicians, 2016.">National Clinical Guideline for Stroke 2016</a>). </p> <p>We did not identify beneficial or hazardous effects of starting versus avoiding longâterm oral antiplatelet therapy, or particular antiplatelet agents, after ICH on the primary outcome of MACE. However, the results ofÂ <a href="./references#CD012144-bbs2-0008" title="Al-Shahi SalmanR , DennisM , MurrayG , InnesK , DreverJ , DinsmoreL , et al. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. Trials2018;19:162. [DOI: 10.1186/s13063-018-2542-6]Al-Shahi SalmanR , MinksDP , MitraD , RodriguesMA , BhatnagarP , du PlessisJC , RESTART Collaboration. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology2019;18(7):643-52. [DOI: 10.1016/S1474-4422(19)30184-X] [PMID: 31129065]RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet2019;393(10191):2613-23. [DOI: 10.1016/S0140-6736(19)30840-2] [PMID: 31128924]">RESTART 2019</a>Â provide some reassurance about the hazards of antiplatelet therapy after ICH (<a href="./references#CD012144-fig-0027" title="">Analysis 3.6</a>) as well as the potential for a reduction in stroke, myocardial infarction or vascular death (<a href="./references#CD012144-fig-0033" title="">Analysis 3.12</a>;Â <a href="./references#CD012144-bbs2-0031" title="Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet2009;373:1849-60. [DOI: 10.1016/S0140-6736(09)60503-1]">Antithrombotic Trialists' Collaboration 2009</a>). Consequently, guidelines that followed the publication ofÂ <a href="./references#CD012144-bbs2-0008" title="Al-Shahi SalmanR , DennisM , MurrayG , InnesK , DreverJ , DinsmoreL , et al. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. Trials2018;19:162. [DOI: 10.1186/s13063-018-2542-6]Al-Shahi SalmanR , MinksDP , MitraD , RodriguesMA , BhatnagarP , du PlessisJC , RESTART Collaboration. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology2019;18(7):643-52. [DOI: 10.1016/S1474-4422(19)30184-X] [PMID: 31129065]RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet2019;393(10191):2613-23. [DOI: 10.1016/S0140-6736(19)30840-2] [PMID: 31128924]">RESTART 2019</a>Â have concluded that antiplatelet therapy may be considered for survivors of antithrombotic drugâassociated ICH (<a href="./references#CD012144-bbs2-0034" title="ShoamaneshA , LindsayMP , CastellucciLA , CayleyA , CrowtherM , deWitK , et al. Canadian stroke best practice recommendations: nanagement of spontaneous intracerebral hemorrhage, 7th edition update 2020. International Journal of Stroke2021;16:321-41. [DOI: 10.1177/1747493020968424]">Canadian ICH best practice recommendation 2020</a>;Â <a href="./references#CD012144-bbs2-0039" title="CaoY , YuS , ZhangQ , Â YuT , LiuY , SunZ , et al. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of intracerebral haemorrhage. Stroke and Vascular Neurology2020;5:396-402. [DOI: 10.1136/svn-2020-000433]">Chinese Stroke Association guidelines 2019</a>). </p> </section> <h3 class="title" id="CD012144-sec-0082">Implications for research</h3> <section id="CD012144-sec-0082"> <p>More RCTs are required to resolve the ongoing uncertainties about antithrombotic treatment after ICH. These RCTs should be at low risk of bias and sufficiently large to reliably exclude or confirm the direction and magnitude of the effects suggested by our pooled analyses of pilot phase RCTs. Even if some of these RCTs recruit an insufficient sample size to be conclusive in their own right, their data will contribute substantially to a further update of this Cochrane Review, which will increase the precision and certainty of the pooled estimates of effects. </p> <p>We are not aware of any ongoing RCTs investigating the effects of starting versus avoiding shortâterm prophylactic dose anticoagulation after ICH. Further RCTs seem justified if there is uncertainty in clinical practice about using prophylactic dose anticoagulation in addition to intermittent pneumatic compression in clinical practice. Â  </p> <p>Several ongoing RCTs are investigating the effects of starting versus avoiding longâterm therapeutic dose oral anticoagulation for AF after ICH (<a href="./references#CD012144-bbs2-0023" title="NCT03186729. STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage (STATICH). https://clinicaltrials.gov/ct2/show/NCT03186729 (first received 14 June 2017). [NCT03186729]">NCT03186729</a>;Â <a href="./references#CD012144-bbs2-0024" title="NCT03243175. Avoiding Anticoagulation After IntraCerebral Haemorrhage (A3ICH). https://clinicaltrials.gov/ct2/show/NCT03243175 (first received 8 August 2017). [NCT03243175]">NCT03243175</a>;Â <a href="./references#CD012144-bbs2-0025" title="NCT03907046. Anticoagulation for stroke prevention and recovery after ICH (ASPIRE). https://clinicaltrials.gov/ct2/show/NCT03907046 (first received 8 April 2019). [NCT03907046]">NCT03907046</a>;Â <a href="./references#CD012144-bbs2-0026" title="NCT03950076. EdoxabaN foR IntraCranial Hemorrhage survivors with Atrial Fibrillation (ENRICH-AF). Cochrane Database of Systematic Reviews (first received 15 May 2019). ">NCT03950076</a>;Â <a href="./references#CD012144-bbs2-0029" title="HaasK , KorompokiE , HugenK , MalzahnU , RuckerV , HarveyK , et al. Prevention of stroke in intracerebral haemorrhage survivors with atrial fibrillation (PRESTIGE-AF): objectives and design of a randomised clinical trial and an observational study. European Stroke Journal2018;3 Suppl 1:233. [DOI: 10.1177/2396987318770127]">PRESTIGEâAF</a>). Some of these RCTs may be conclusive in their own right when completed, but together they should certainly provide sufficient data for an update of this Cochrane Review to be conclusive about our primary and secondary outcomes. Further RCTs do not appear to be required to investigate effects overall, but large numbers of participants will be required to investigate heterogeneity of effects in subgroups. The emphasis should be on completing recruitment to the ongoing RCTs as soon as possible. </p> <p>Some ongoing RCTs are investigating the effects of starting versus avoiding longâterm antiplatelet therapy after ICH (<a href="./references#CD012144-bbs2-0022" title="NCT02966119. REstart or STop Antithrombotic Randomised Trial in France (RESTART-Fr). https://clinicaltrials.gov/ct2/show/NCT02966119 (first received 17 November 2016). [NCT02966119]">NCT02966119</a>;Â <a href="./references#CD012144-bbs2-0023" title="NCT03186729. STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage (STATICH). https://clinicaltrials.gov/ct2/show/NCT03186729 (first received 14 June 2017). [NCT03186729]">NCT03186729</a>;Â <a href="./references#CD012144-bbs2-0027" title="NCT04522102. Antiplatelet Secondary Prevention International Randomised trial after INtracerebral haemorrhaGe (ASPIRING) - pilot phase. https://clinicaltrials.gov/ct2/show/NCT04522102 (first received 21 August 2020). ">NCT04522102</a>;Â <a href="./references#CD012144-bbs2-0028" title="NCT04820972. Early-start antiplatelet treatment after neurosurgery in patients with spontaneous intracerebral hemorrhage. https://clinicaltrials.gov/ct2/show/NCT04820972 (first received 29 March 2021). ">NCT04820972</a>). However, the sample sizes of these RCTs make each of them very unlikely to be definitive about effects on our primary and secondary outcomes, and they are unlikely to be definitive when pooled, sinceÂ <a href="./references#CD012144-bbs2-0027" title="NCT04522102. Antiplatelet Secondary Prevention International Randomised trial after INtracerebral haemorrhaGe (ASPIRING) - pilot phase. https://clinicaltrials.gov/ct2/show/NCT04522102 (first received 21 August 2020). ">NCT04522102</a>Â estimates that more than 4000 participants are required to generate definitive evidence about starting versus avoiding longâterm antiplatelet therapy after ICH. Therefore, a further, large, definitive RCT seems justified to investigate effects both overall and in subgroups. If starting antiplatelet therapy proves to be beneficial, then further RCTs comparing different antiplatelet agents would be justified. </p> <p>Only one ongoing RCT is comparing the effects of longâterm therapeutic dose oral anticoagulation for AF after ICH to the left atrial appendage closure device (<a href="./references#CD012144-bbs2-0024" title="NCT03243175. Avoiding Anticoagulation After IntraCerebral Haemorrhage (A3ICH). https://clinicaltrials.gov/ct2/show/NCT03243175 (first received 8 August 2017). [NCT03243175]">NCT03243175</a>), although another RCT is comparing the left atrial appendage closure device to any antithrombotic prescribing strategy for the same indication (STROKECLOSE, <a href="https://clinicaltrials.gov/ct2/show/NCT02830152" target="_blank">NCT02830152</a>). If longâterm therapeutic dose oral anticoagulation for AF after ICH is beneficial as suggested by this review (<a href="./references#CD012144-fig-0011" title="">Analysis 2.1</a>), the nonâinferiority or superiority of this device to longâterm therapeutic dose oral anticoagulation will need to be investigated. </p> <p>Further updates of this Cochrane Review and the individual participant data metaâanalysis planned by the Collaboration Of Controlled Randomised trials of Oral Antithrombotic agents after intraCranial Haemorrhage (COCROACH, <a href="https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021246133" target="_blank">CRD42021246133</a>) will be required to provide the most precise estimates of the effects of antithrombotic treatments after stroke due to ICH. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012144-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012144-sec-0008"></div> <div class="table" id="CD012144-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Summary of findings table â Starting shortâterm prophylactic dose anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Starting shortâterm prophylactic dose anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> survivors of stroke due to intracerebral haemorrhage<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> starting shortâterm prophylactic dose anticoagulation<br/><b>Comparison:</b> avoiding anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with avoiding anticoagulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with starting shortâterm prophylactic dose anticoagulation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MACE â not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death<br/>assessed with: clinical assessment<br/>followâup: 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>175 per 1000</b><br/>(103 to 297) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.59 to 1.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venous thromboembolism<br/>assessed with: clinical assessment<br/>followâup: 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b><br/>(72 to 195) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b><br/>(0.51 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intracerebral haemorrhage (ICH)<br/>assessed with: brain imaging and clinical assessment<br/>followâup: 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><br/>(4 to 143) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.24</b><br/>(0.04 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functional status: mRS 0â2<br/>assessed with: clinical assessment<br/>followâup: 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>290 per 1000</b><br/>(111 to 750) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.03</b><br/>(0.78 to 5.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424458755853554175" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424458755853554175</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The included RCTs have serious risk of bias due to lack of blinding to treatment, and random sequence generation and allocation concealment not being adequately described.<br/><sup>b</sup> The optimal information size (OIS) criterion is not met. The sample size of this study is probably lower than the minimum number of participants required for a trial adequately powered to identify a statistically significant difference for this outcome.<br/><sup>c</sup> Very small pooled sample size<br/><sup>d</sup> Low pooled sample size and event rate<br/><sup>e</sup> Extremely small pooled sample size </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012144-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Summary of findings table â Starting longâterm therapeutic dose oral anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage with atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Starting longâterm therapeutic dose oral anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage with atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> survivors of stroke due to intracerebral haemorrhage with atrial fibrillation <br/><b>Setting:</b> Secondary care<br/><b>Intervention:</b> starting longâterm therapeutic dose oral anticoagulation<br/><b>Comparison:</b> avoiding anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with avoiding anticoagulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with starting longâterm therapeutic dose oral anticoagulation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MACE (MACE)<br/>assessed with: clinical assessment<br/>followâup: range 1 years to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>158 per 1000</b><br/>(104 to 244) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.61</b><br/>(0.40 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death<br/>assessed with: clinical assessment<br/>followâup: range 1 years to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b><br/>(84 to 242) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/>(0.62 to 1.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All major occlusive vascular events<br/>assessed with: clinical assessment<br/>followâup: range 1 years to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b><br/>(29 to 111) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.27</b><br/>(0.14 to 0.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intracranial haemorrhage<br/>assessed with: clinical assessment<br/>followâup: range 1 years to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b><br/>(27 to 208) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.43</b><br/>(0.88 to 6.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functional status (mRS 0â2)<br/>assessed with: clinical assessment<br/>followâup: 1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>490 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b><br/>(382 to 607) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b><br/>(0.78 to 1.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low<sup>b,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431448658702855854" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431448658702855854</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> All included randomised trials were open label, but these outcomes were objective.<br/><sup>b</sup> These are the results of a small number of events being observed in three RCTs with relatively small sample sizes.<br/><sup>c</sup> The pooled estimate was imprecise due to the small number of outcome events<br/><sup>d</sup> All included randomised trials were open label, and this outcome was subjective </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012144-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Summary of findings table â Starting longâterm oral antiplatelet therapy compared to avoiding antithrombotic therapy for survivors of stroke due to intracerebral haemorrhage</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Starting longâterm oral antiplatelet therapy compared to avoiding antithrombotic therapy for survivors of stroke due to intracerebral haemorrhage</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> survivors of stroke due to intracerebral haemorrhage<br/><b>Setting:</b> Secondary care<br/><b>Intervention:</b> starting longâterm oral antiplatelet therapy<br/><b>Comparison:</b> avoiding antithrombotic therapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with avoiding antithrombotic therapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with starting longâterm oral antiplatelet therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MACE<br/>assessed with: clinical assessment<br/>followâup: median 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>228 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>203 per 1000</b><br/>(146 to 278) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b><br/>(0.64 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death<br/>assessed with: clinical assessment<br/>followâup: median 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b><br/>(142 to 285) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b><br/>(0.76 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All major occlusive vascular events<br/>assessed with: clinical assessment<br/>followâup: median 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b><br/>(96 to 220) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b><br/>(0.68 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intracerebral haemorrhage (ICH)<br/>assessed with: clinical assessment<br/>followâup: median 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b><br/>(23 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.52</b><br/>(0.27 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fnctional status (mRS 0â2)<br/>assessed with: clinical assessment<br/>followâup: 1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>433 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>411 per 1000</b><br/>(333 to 511) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/>(0.77 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>461<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431448890153987933" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431448890153987933</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The included randomised trial was open label but outcomes were objective.<br/><sup>b</sup> Only one randomised trial with 537 participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012144-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span>Â <span class="table-title">Summary of findings table â Cilostazol compared to aspirin for adults within 180 days of nonâcardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral haemorrhage</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cilostazol compared to aspirin for adults within 180 days of nonâcardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral haemorrhage</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults within 180 days of nonâcardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral haemorrhage<br/><b>Setting:</b> Secondary care<br/><b>Intervention:</b> cilostazol<br/><b>Comparison:</b> aspirin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with aspirin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with cilostazol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MACE<br/>assessed with: clinical assessment<br/>followâup: median 1.8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>116 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>155 per 1000</b><br/>(86 to 279) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b><br/>(0.74 to 2.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death<br/>assessed with: clinical assessment<br/>followâup: median 1.8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b><br/>(19 to 168) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.65</b><br/>(0.55 to 4.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All major occlusive vascular events â not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intracerebral haemorrhage (ICH)<br/>assessed with: clinical assessment<br/>followâup: median 1.8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b><br/>(10 to 128) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b><br/>(0.35 to 4.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functional status â not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431449016706363235" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431449016706363235</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The report of the subâgroup of the PICASSO trial did not report major extracerebral haemorrhage, DVT or functional status.<br/><sup>b</sup> Small sample size from a subâgroup of the PICASSO trial </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012144-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012144-sec-0009"></div> <p>Stroke was the secondâleading cause of death worldwide in 2019, when stroke due to spontaneous (nonâtraumatic) intracerebral haemorrhage (ICH) constituted 28% of all incident strokes and 48% of disabilityâadjusted life years due to stroke (<a href="./references#CD012144-bbs2-0045" title="GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurology2021;20:795-820. [DOI: 10.1016/S1474-4422(21)00252-0]">GBD 2019 Stroke Collaborators 2021</a>). Half of those patients with ICH die within one year (mostly due to the ICH), leaving 20.7 million prevalent ICH survivors worldwide (<a href="./references#CD012144-bbs2-0045" title="GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurology2021;20:795-820. [DOI: 10.1016/S1474-4422(21)00252-0]">GBD 2019 Stroke Collaborators 2021</a>). ICH survivors are at high risk of major adverse cardiovascular events (MACE), such as stroke, myocardial infarction, and death due to a vascular cause. Antithrombotic drugs (<a href="#CD012144-tbl-0005">Table 1</a>) reduce the risk of MACE overall for many patients, by reducing the risk of ischaemic events despite an increase in the risk of haemorrhagic events. However, the effects of antithrombotic drugs on ICH survivors are uncertain, which makes this a common therapeutic dilemma in everyday clinical practice. </p> <div class="table" id="CD012144-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span>Â <span class="table-title">Nonâenzymatic antithrombotic agents with defined daily doses within group B01A of the World Health Organization Anatomical Therapeutic Chemical Classification System</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Antithrombotic class</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Antithrombotic agents</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vitamin K antagonists</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dicoumarol, phenindione, warfarin, phenprocoumon, acenocoumarol, ethyl biscoumacetate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heparin group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heparin, antithrombin III, dalteparin, enoxaparin, nadroparin, parnaparin, reviparin, danaparoid, tinzaparin, sulodexide, bemiparin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Platelet aggregation inhibitors excluding heparin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clopidogrel, ticlopidine, acetylsalicylic acid, dipyridamole, carbasalate calcium, epoprostenol, indobufen, iloprost, abciximab, aloxiprin, eptifibatide, tirofiban, triflusal, beraprost, treprostinil, prasugrel, cilostazol, ticagrelor, cangrelor, vorapaxar, selexipag </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Direct thrombin inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Desirudin, lepirudin, argatroban, melagatran, ximelagatran, bivalirudin, dabigatran etexilate* </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Direct factor Xa inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rivaroxaban*, apixaban*, edoxaban*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other antithrombotic agents</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defibrotide, fondaparinux</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><a href="https://www.whocc.no/atc_ddd_index/?code=B01A" target="_blank">www.whocc.no/atc_ddd_index/?code=B01A</a> </p> <p>* Nonâvitamin K (direct) oral anticoagulants</p> </div> </div> <section id="CD012144-sec-0010"> <h3 class="title" id="CD012144-sec-0010">Description of the condition</h3> <p>Survivors of ICH are at high risk of ischaemic and haemorrhagic MACE. Cerebral small vessel diseases, which underlie more than 85% of ICH (<a href="./references#CD012144-bbs2-0060" title="SamarasekeraN , FonvilleA , LerpiniereC , FarrallAJ , WardlawJM , WhitePM , et al. Influence of intracerebral hemorrhage location on incidence, characteristics, and outcome: population-based study. Stroke2015;46:361-8. [DOI: 10.1161/STROKEAHA.114.007953]">Samarasekera 2015</a>), may also cause ischaemic stroke and vascular dementia. Adults with ICH are approximately 75 years old and usually have high blood pressure (BP), multiple coâmorbidities, and other risk factors for ischaemic or haemorrhagic MACE, which have already affected one third of adults before their ICH (<a href="./references#CD012144-bbs2-0045" title="GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurology2021;20:795-820. [DOI: 10.1016/S1474-4422(21)00252-0]">GBD 2019 Stroke Collaborators 2021</a>;Â <a href="./references#CD012144-bbs2-0051" title="LiL , PoonMT , SamarasekeraNE , PerryLA , MoullaaliTJ , RodriguesMA , et al. Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies. Lancet Neurology2021;20:437-47. [DOI: 10.1016/S1474-4422(21)00075-2]">Li 2021</a>). Survivors of ICH are at higher future risk of ischaemic MACE than population controls (<a href="./references#CD012144-bbs2-0044" title="GaistD , Gonzalez-PerezA , HaldSM , Garcia RodriguezLA . Higher risk of ischemic stroke after an intracerebral hemorrhage than in general population: a cohort study from the United Kingdom. Stroke2022;53(2):e50-e52. [DOI: 10.1161/STROKEAHA.121.037633]">Gaist 2022</a>;Â <a href="./references#CD012144-bbs2-0052" title="MurthySB , ZhangC , DiazI , LevitanEB , KotonS , BartzTM , et al. Association between intracerebral hemorrhage and subsequent arterial ischemic events in participants from 4 population-based cohort studies. JAMA Neurology2021;78:809-16. [DOI: 10.1001/jamaneurol.2021.0925]">Murthy 2021</a>). Overall, the rate of ischaemic MACE appears to exceed the rate of recurrent ICH, and these rates appear higher early after ICH (<a href="./references#CD012144-bbs2-0032" title="BanerjeeG , WilsonD , AmblerG , HostettlerIC , ShakeshaftC , CohenH , et al. Longer term stroke risk in intracerebral haemorrhage survivors. Journal of Neurology, Neurosurgery and Psychiatry2020;91:840-5. [DOI: 10.1136/jnnp-2020-323079]">Banerjee 2020</a>;Â <a href="./references#CD012144-bbs2-0051" title="LiL , PoonMT , SamarasekeraNE , PerryLA , MoullaaliTJ , RodriguesMA , et al. Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies. Lancet Neurology2021;20:437-47. [DOI: 10.1016/S1474-4422(21)00075-2]">Li 2021</a>;Â <a href="./references#CD012144-bbs2-0058" title="PoonMT , FonvilleAF , Al-Shahi SalmanR . Long-term prognosis after intracerebral haemorrhage: systematic review and metaanalysis. Journal of Neurology, Neurosurgery and Psychiatry2014;85(6):660-7. [DOI: 10.1136/jnnp-2013-306476]">Poon 2014</a>). If ICH is in a lobar location recurrent ICH is more likely, whereas atrial fibrillation (AF) is the main risk factor for ischaemic stroke after ICH (<a href="./references#CD012144-bbs2-0032" title="BanerjeeG , WilsonD , AmblerG , HostettlerIC , ShakeshaftC , CohenH , et al. Longer term stroke risk in intracerebral haemorrhage survivors. Journal of Neurology, Neurosurgery and Psychiatry2020;91:840-5. [DOI: 10.1136/jnnp-2020-323079]">Banerjee 2020</a>;Â <a href="./references#CD012144-bbs2-0035" title="CasollaB , MoulinS , KyhengM , HÃ©nonH , LabreucheJ , LeysD , et al. Five-year risk of major ischemic and hemorrhagic events after intracerebral hemorrhage. Stroke2019;50:1100-7. [DOI: 10.1161/STROKEAHA.118.024449]">Casolla 2019</a>;Â <a href="./references#CD012144-bbs2-0051" title="LiL , PoonMT , SamarasekeraNE , PerryLA , MoullaaliTJ , RodriguesMA , et al. Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies. Lancet Neurology2021;20:437-47. [DOI: 10.1016/S1474-4422(21)00075-2]">Li 2021</a>;Â <a href="./references#CD012144-bbs2-0054" title="NielsenPB , MelgaardL , OvervadTF , JensenM , LarsenTB , Â LipGY , et al. Risk of cerebrovascular events in intracerebral hemorrhage survivors with atrial fibrillation: a nationwide cohort study. Stroke2022;53:2559-68. [DOI: 10.1161/STROKEAHA.121.038331]">Nielsen 2022</a>). In populationâbased cohort studies of incident ICH in the UK, the annual rate of MACE ranged from 7% to 19%, dependent on survivorsâ medical history (<a href="./references#CD012144-bbs2-0051" title="LiL , PoonMT , SamarasekeraNE , PerryLA , MoullaaliTJ , RodriguesMA , et al. Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies. Lancet Neurology2021;20:437-47. [DOI: 10.1016/S1474-4422(21)00075-2]">Li 2021</a>). These rates are even higher in lowâmiddle income countries (<a href="./references#CD012144-bbs2-0037" title="ChenY , WrightN , GuoY , TurnbullI , KartsonakiC , YangL , et al. Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0.5 million Chinese adults. Lancet Global Health2020;8:e580-e590. [DOI: 10.1016/S2214-109X(20)30069-3]">Chen 2020</a>). Most people with MACE after ICH die or are left disabled, so they cause a huge burden on health and care services worldwide (<a href="./references#CD012144-bbs2-0045" title="GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurology2021;20:795-820. [DOI: 10.1016/S1474-4422(21)00252-0]">GBD 2019 Stroke Collaborators 2021</a>;Â <a href="./references#CD012144-bbs2-0051" title="LiL , PoonMT , SamarasekeraNE , PerryLA , MoullaaliTJ , RodriguesMA , et al. Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies. Lancet Neurology2021;20:437-47. [DOI: 10.1016/S1474-4422(21)00075-2]">Li 2021</a>). </p> </section> <section id="CD012144-sec-0011"> <h3 class="title" id="CD012144-sec-0011">Description of the intervention</h3> <p>The only intervention proven to reduce stroke after ICH is BP lowering (<a href="./references#CD012144-bbs2-0036" title="ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et alÂ . Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116-21. [DOI: 10.1161/01.STR.0000106480.76217.6F]">Chapman 2004</a>), and most guidelines focus on prevention of recurrent ICH (<a href="./references#CD012144-bbs2-0030" title="Hemphill JC 3rd, GreenbergSM , AndersonCS , BeckerK , BendokBR , CushmanM , et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2015;46:2032-60. [DOI: 10.1161/STR.0000000000000069]">AHA ICH guideline 2015</a>;Â <a href="./references#CD012144-bbs2-0034" title="ShoamaneshA , LindsayMP , CastellucciLA , CayleyA , CrowtherM , deWitK , et al. Canadian stroke best practice recommendations: nanagement of spontaneous intracerebral hemorrhage, 7th edition update 2020. International Journal of Stroke2021;16:321-41. [DOI: 10.1177/1747493020968424]">Canadian ICH best practice recommendation 2020</a>;Â <a href="./references#CD012144-bbs2-0039" title="CaoY , YuS , ZhangQ , Â YuT , LiuY , SunZ , et al. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of intracerebral haemorrhage. Stroke and Vascular Neurology2020;5:396-402. [DOI: 10.1136/svn-2020-000433]">Chinese Stroke Association guidelines 2019</a>;Â <a href="./references#CD012144-bbs2-0042" title="KlijnCJ , PaciaroniM , BergeE , KorompokiE , KÃµrvJ , LalA , et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline. European Stroke Journal2019;4:198-223. [DOI: 10.1177/2396987319841187]">ESO guideline on antithrombotic treatment 2019</a>;Â <a href="./references#CD012144-bbs2-0043" title="SteinerT , Al-Shahi SalmanR , BeerR , ChristensenH , Cordonnier, CsibaL , et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. International Journal of Stroke2014;9:840-55. [DOI: 10.1111/ijs.12309]">ESO ICH Guideline 2014</a>;Â <a href="./references#CD012144-bbs2-0053" title="Intercollegiate Stroke Working Party. Royal College of Physicians. 5th edition. London, UK: Royal College of Physicians, 2016.">National Clinical Guideline for Stroke 2016</a>). However, despite widespread implementation of BP lowering after ICH, which has been associated with better BP control and outcome, the annual rate of all MACE for ICH survivors has remained between 7% and 19% in the last two decades (<a href="./references#CD012144-bbs2-0032" title="BanerjeeG , WilsonD , AmblerG , HostettlerIC , ShakeshaftC , CohenH , et al. Longer term stroke risk in intracerebral haemorrhage survivors. Journal of Neurology, Neurosurgery and Psychiatry2020;91:840-5. [DOI: 10.1136/jnnp-2020-323079]">Banerjee 2020</a>;Â <a href="./references#CD012144-bbs2-0035" title="CasollaB , MoulinS , KyhengM , HÃ©nonH , LabreucheJ , LeysD , et al. Five-year risk of major ischemic and hemorrhagic events after intracerebral hemorrhage. Stroke2019;50:1100-7. [DOI: 10.1161/STROKEAHA.118.024449]">Casolla 2019</a>;Â <a href="./references#CD012144-bbs2-0037" title="ChenY , WrightN , GuoY , TurnbullI , KartsonakiC , YangL , et al. Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0.5 million Chinese adults. Lancet Global Health2020;8:e580-e590. [DOI: 10.1016/S2214-109X(20)30069-3]">Chen 2020</a>;Â <a href="./references#CD012144-bbs2-0051" title="LiL , PoonMT , SamarasekeraNE , PerryLA , MoullaaliTJ , RodriguesMA , et al. Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies. Lancet Neurology2021;20:437-47. [DOI: 10.1016/S1474-4422(21)00075-2]">Li 2021</a>;Â <a href="./references#CD012144-bbs2-0058" title="PoonMT , FonvilleAF , Al-Shahi SalmanR . Long-term prognosis after intracerebral haemorrhage: systematic review and metaanalysis. Journal of Neurology, Neurosurgery and Psychiatry2014;85(6):660-7. [DOI: 10.1136/jnnp-2013-306476]">Poon 2014</a>). Therefore, better secondary prevention of all MACE after ICH is needed in standard clinical practice. </p> <p>Antithrombotic drugs, which have various mechanisms of action (<a href="#CD012144-tbl-0005">Table 1</a>), are usually dichotomised into antiplatelet and anticoagulant drugs according to their use in clinical practice. These drugs reduce the risk of thrombosis and thromboembolism, but consequently increase the risk of bleeding. Anticoagulation may be prescribed in lower 'prophylactic' doses for prevention of venous thromboembolism for immobile patients, or higher 'therapeutic doses' for prevention of systemic embolism for patients in AF. The anticoagulant drugs used subcutaneously at a lower dose for prophylaxis are from the heparin group, whereas the anticoagulants used orally at a therapeutic dose for AF are the vitamin K antagonists, direct thrombin inhibitors, and direct factor Xa inhibitors (<a href="#CD012144-tbl-0005">Table 1</a>). The antiplatelet drugs used orally for prevention of occlusive vascular events are the platelet aggregation inhibitors (<a href="#CD012144-tbl-0005">Table 1</a>). </p> </section> <section id="CD012144-sec-0012"> <h3 class="title" id="CD012144-sec-0012">How the intervention might work</h3> <p>Antiplatelet drugs disrupt the formation of platelet plugs. They are used for preventing arterial thromboembolism, such as myocardial infarction or ischaemic stroke. Aspirin achieves this by inhibiting platelet activation, while clopidogrel, cilostazol and tirofiban impede aggregation. </p> <p>Anticoagulant drugs disrupt the coagulation cascade to stop a fibrin mesh forming around the platelet plug and are generally used to prevent venous thromboembolism. Heparin and enoxaparin bind to a naturally occurring anticoagulant (antithrombin) to amplify its effect, while direct (nonâvitamin K) oral anticoagulants (DOACs) and warfarin directly inhibit the coagulation cascade. </p> <p>Antithrombotic drugs also increase the risk of bleeding as a result of their effect on clotting and platelet aggregation. </p> <p>Although antithrombotic drugs are known to be of net benefit (i.e. when considering their effects on both clotting and bleeding) in people without a history of bleeding (<a href="./references#CD012144-bbs2-0031" title="Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet2009;373:1849-60. [DOI: 10.1016/S0140-6736(09)60503-1]">Antithrombotic Trialists' Collaboration 2009</a>;Â <a href="./references#CD012144-bbs2-0033" title="BenzAP , JohanssonI , DewildeWJ , LopesRD , MehranR , SartoriS , et al. Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. European Heart Journal - Cardiovascular Pharmacotherapy 2021 Jun 17 [Epub ahead of print]. [DOI: 10.1093/ehjcvp/pvab044]">Benz 2021</a>;Â <a href="./references#CD012144-bbs2-0047" title="HartRG , PearceLA , AguilarMI . Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine2007;146:857-67. [DOI: 10.7326/0003-4819-146-12-200706190-00007]">Hart 2007</a>), the balance of benefit and harm is uncertain after ICH. </p> </section> <section id="CD012144-sec-0013"> <h3 class="title" id="CD012144-sec-0013">Why it is important to do this review</h3> <p>People with ICH were excluded from randomised controlled trials (RCTs) of prophylactic dose anticoagulation after acute stroke (<a href="./references#CD012144-bbs2-0063" title="WangX , OuyangM , YangJ , SongL , YangM , AndersonCS . Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews2021, Issue 10. Art. No: CD000024. [CENTRAL: CD000024] [DOI: 10.1002/14651858.CD000024.pub5]">Wang 2021</a>), and secondary prevention of MACE with antiplatelet therapy (<a href="./references#CD012144-bbs2-0031" title="Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet2009;373:1849-60. [DOI: 10.1016/S0140-6736(09)60503-1]">Antithrombotic Trialists' Collaboration 2009</a>;Â <a href="./references#CD012144-bbs2-0033" title="BenzAP , JohanssonI , DewildeWJ , LopesRD , MehranR , SartoriS , et al. Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. European Heart Journal - Cardiovascular Pharmacotherapy 2021 Jun 17 [Epub ahead of print]. [DOI: 10.1093/ehjcvp/pvab044]">Benz 2021</a>), or therapeutic dose anticoagulation for AF (<a href="./references#CD012144-bbs2-0047" title="HartRG , PearceLA , AguilarMI . Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine2007;146:857-67. [DOI: 10.7326/0003-4819-146-12-200706190-00007]">Hart 2007</a>). </p> <p>A network metaâanalysis of RCTs of pharmacological thromboprophylaxis versus intermittent pneumatic compression to prevent venous thromboembolism after ICH was unable to make meaningful comparisons between prophylactic dose anticoagulation and the current clinical standard of care with intermittent pneumatic compression (<a href="./references#CD012144-bbs2-0064" title="YogendrakumarIV , LunR , KhanF , SalottoloK , LacutK , GrahamC , et al. Venous thromboembolism prevention in intracerebral hemorrhage: a systematic review and network meta-analysis. PLOS One2020;15:e0234957. [DOI: 10.1371/journal.pone.0234957]">Yogendrakumar 2020</a>). </p> <p>A systematic review and metaâanalysis of cohort studies of patients with any type of intracranial haemorrhage (i.e. intracerebral, subarachnoid, or subdural haemorrhage) found lower risks of ischaemic MACE (risk ratio (RR) 0.61, 95% confidence interval (CI) 0.48 to 0.79) and no evidence of a difference in haemorrhagic MACE risk (RR 0.84, 95 %CI 0.47 to 1.51) associated with resumption compared with avoidance of antiplatelet therapy (<a href="./references#CD012144-bbs2-0041" title="DingX , LiuX , TanC , YinM , WangT , LiuY , et al. Resumption of antiplatelet therapy in patients with primary intracranial hemorrhage-benefits and risks: a meta-analysis of cohort studies. Journal of the Neurological Sciences2018;384:133-8. [DOI: 10.1016/j.jns.2017.11.009]">Ding 2018</a>). </p> <p>A systematic review and metaâanalysis of cohort studies of patients with spontaneous intracranial haemorrhage and AF comparing oral anticoagulation with either antiplatelet agents or no antithrombotic therapy mostly found associations between oral anticoagulation and lower risks of ischaemic MACE, but no significant change in the risk of haemorrhagic MACE, although these studies are susceptible to selection bias (<a href="./references#CD012144-bbs2-0050" title="KorompokiE , FilippidisFT , NielsenPB , Del GiudiceA , LipGY , KuramatsuJB , et al. Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology2017;89:687-96. [DOI: 10.1212/WNL.0000000000004235]">Korompoki 2017</a>). </p> <p>The evidence available has left guidelines unable to recommend antithrombotic drugs after ICH (<a href="./references#CD012144-bbs2-0030" title="Hemphill JC 3rd, GreenbergSM , AndersonCS , BeckerK , BendokBR , CushmanM , et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2015;46:2032-60. [DOI: 10.1161/STR.0000000000000069]">AHA ICH guideline 2015</a>;Â <a href="./references#CD012144-bbs2-0034" title="ShoamaneshA , LindsayMP , CastellucciLA , CayleyA , CrowtherM , deWitK , et al. Canadian stroke best practice recommendations: nanagement of spontaneous intracerebral hemorrhage, 7th edition update 2020. International Journal of Stroke2021;16:321-41. [DOI: 10.1177/1747493020968424]">Canadian ICH best practice recommendation 2020</a>;Â <a href="./references#CD012144-bbs2-0039" title="CaoY , YuS , ZhangQ , Â YuT , LiuY , SunZ , et al. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of intracerebral haemorrhage. Stroke and Vascular Neurology2020;5:396-402. [DOI: 10.1136/svn-2020-000433]">Chinese Stroke Association guidelines 2019</a>;Â <a href="./references#CD012144-bbs2-0043" title="SteinerT , Al-Shahi SalmanR , BeerR , ChristensenH , Cordonnier, CsibaL , et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. International Journal of Stroke2014;9:840-55. [DOI: 10.1111/ijs.12309]">ESO ICH Guideline 2014</a>;Â <a href="./references#CD012144-bbs2-0042" title="KlijnCJ , PaciaroniM , BergeE , KorompokiE , KÃµrvJ , LalA , et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline. European Stroke Journal2019;4:198-223. [DOI: 10.1177/2396987319841187]">ESO guideline on antithrombotic treatment 2019</a>;Â <a href="./references#CD012144-bbs2-0053" title="Intercollegiate Stroke Working Party. Royal College of Physicians. 5th edition. London, UK: Royal College of Physicians, 2016.">National Clinical Guideline for Stroke 2016</a>). Consequently, there has been variation in clinical practice, evident from the proportion of patients starting antithrombotic drugs after ICH varying between 11% to 45% in different countries (<a href="./references#CD012144-bbs2-0056" title="PasquiniM , CharidimouA , Van AschCJ , BaharogluMI , SamarasekeraN , WerringDJ , et al. Variation in restarting antithrombotic drugs at hospital discharge after ICH. Stroke2014;45(9):2643-8. [DOI: 10.1161/STROKEAHA.114.006202]">Pasquini 2014</a>). </p> <p>In the most recent version of this Cochrane Review, we analysed two RCTs including 121 participants, and concluded that there was insufficient evidence from RCTs to support or discourage the use of antithrombotic treatment after ICH (<a href="./references#CD012144-bbs2-0066" title="PerryLA , BergeE , BowditchJ , ForfangE , RÃ¸nningOM , HankeyGJ , VillanuevaE , Al-Shahi SalmanR . Antithrombotic treatment after stroke due to intracerebral haemorrhage. Cochrane Database of Systematic Reviews2017, Issue 5. Art. No: CD012144. [CENTRAL: CD012144] [DOI: 10.1002/14651858.CD012144.pub2] [PMID: 28540976]">Perry 2017</a>). However, several RCTs have been published since the first version of this review, therefore we performed this update. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012144-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012144-sec-0014"></div> <p>To determine the overall effectiveness and safety of antithrombotic drugs on major adverse cardiovascular events (MACE) and its components for people with ICH. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012144-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012144-sec-0015"></div> <section id="CD012144-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012144-sec-0017"> <h4 class="title">Types of studies</h4> <p>We sought all randomised controlled trials (RCTs) that made comparisons of starting versus avoiding antithrombotic drugs, or direct comparisons of different antithrombotic classes or agents after stroke due to intracerebral haemorrhage (ICH). We included RCTs published in any language and planned to arrange translation where the language of publication was not English. </p> </section> <section id="CD012144-sec-0018"> <h4 class="title">Types of participants</h4> <p>Eligible patients survived spontaneous ICH in the brain parenchyma diagnosed by computed tomography (CT) or magnetic resonance imaging (MRI) scan. We included patients regardless of whether they were on antithrombotic therapy at the time of ICH. </p> </section> <section id="CD012144-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We sought RCTs that compared starting any antithrombotic drug with avoiding antithrombotic treatment, as well as RCTs that compared different antithrombotic classes or agents (<a href="#CD012144-tbl-0005">Table 1</a>). We placed no constraints on dosage, route of administration, or duration of administration. We separated RCTs investigating shortâterm treatment (e.g. with lowâmolecularâweight heparin (LMH) or unfractionated heparin (UFH) to prevent venous thromboembolism early after ICH onset) from those RCTs investigating longâterm secondary prevention (e.g. with oral anticoagulant or antiplatelet drugs). </p> <p>If the effects of antithrombotic drugs might have been confounded by the administration of another active drug to participants (e.g. if allocation to this additional treatment was not evenly distributed between groups in an RCT, or was not randomly allocated), we planned to explore this in our risk of bias assessment and in sensitivity analyses. </p> </section> <section id="CD012144-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We restricted inclusion to RCTs reporting our clinical primary or secondary outcomes (after seeking information about these outcomes if they were not included in the report of the RCT). </p> <section id="CD012144-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>Composite outcome of all serious vascular events, commonly known as MACE (which we defined as ischaemic stroke, myocardial infarction, other major ischaemic event, ICH, major extracerebral haemorrhage, or vascular death) during the scheduled followâup period. </p> </section> <section id="CD012144-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012144-list-0001"> <li> <p>Death during the scheduled followâup period.</p> </li> <li> <p>The individual components of the composite MACE primary outcome: ischaemic stroke, myocardial infarction, other major ischaemic event (deep vein thrombosis, pulmonary embolism or venous thromboembolism), ICH, major extracerebral haemorrhage, and vascular death. </p> </li> <li> <p>Growth of ICH (as classified/reported by each RCT).</p> </li> <li> <p>Functional status (where measured using validated scales, such as the modified Rankin Scale) at the end of the scheduled followâup period. </p> </li> <li> <p>Cognitive status (where measured using validated scales, such as the Montreal Cognitive Assessment or the Miniâmental State Examination) at the end of the scheduled followâup period. </p> </li> </ul> </p> </section> </section> </section> <section id="CD012144-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for RCTs in any language and planned to arrange for the translation of relevant articles where necessary. </p> <section id="CD012144-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We designed a search strategy with the help of the Cochrane Stroke Groupâs Information Specialist, who ran the searches on the 5 October 2021. </p> <p>We searched the following electronic databases:</p> <p> <ul id="CD012144-list-0002"> <li> <p>Cochrane Stroke Group Trials Register;</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 10) in the Cochrane Library; </p> </li> <li> <p>MEDLINE Ovid, 1946 to October 2021;</p> </li> <li> <p>Embase Ovid, 1946 to October 2021.</p> </li> </ul> </p> <p>We searched the following online registries of clinical trials:</p> <p> <ul id="CD012144-list-0003"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>; searched 5 October 2021); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="https://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>; searched 5 October 2021); </p> </li> <li> <p>In the previous version of this review, we searched the Stroke Trials Registry of the Internet Stroke Center (<a href="http://www.strokecenter.org/trials/" target="_blank">www.strokecenter.org/trials/</a>) on 2 March 2017. </p> </li> </ul> </p> </section> <section id="CD012144-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We screened the reference lists of relevant studies to identify RCTs for potential inclusion in the review. In the event that we could not locate the full text of a RCT, or required a specific data extract, we contacted the researchers or the relevant data sharing platform. </p> </section> </section> <section id="CD012144-sec-0026"> <h3 class="title" id="CD012144-sec-0026">Data collection and analysis</h3> <p>We imported the results of the searches into Covidence, removed duplicates, and applied the following methods to select, extract and analyse data. Review author RASS was not involved in decisions about included studies for which he was the Chief Investigator (<a href="./references#CD012144-bbs2-0008" title="Al-Shahi SalmanR , DennisM , MurrayG , InnesK , DreverJ , DinsmoreL , et al. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. Trials2018;19:162. [DOI: 10.1186/s13063-018-2542-6]Al-Shahi SalmanR , MinksDP , MitraD , RodriguesMA , BhatnagarP , du PlessisJC , RESTART Collaboration. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology2019;18(7):643-52. [DOI: 10.1016/S1474-4422(19)30184-X] [PMID: 31129065]RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet2019;393(10191):2613-23. [DOI: 10.1016/S0140-6736(19)30840-2] [PMID: 31128924]">RESTART 2019</a>Â andÂ <a href="./references#CD012144-bbs2-0009" title="SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurology2021;20(10):842-53. [DOI: 10.1016/S1474-4422(21)00264-7.] [PMID: 34487722]">SoSTART 2021</a>); decisions about these studies were made by review authors AC, CC, and coâauthors without a competing interest. </p> <section id="CD012144-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AC and CC) independently screened titles and abstracts and full texts for eligibility, resolving conflicts by discussion with a third review author to reach consensus. </p> <p>We retrieved fullâtext articles for potentially eligible references, and the same three review authors independently screened these fullâtext articles to identify RCTs for inclusion, and identified and recorded reasons for the exclusion of ineligible studies. We resolved any disagreements through discussion. We collated multiple reports of the same RCT, and chose the report at lowest risk of bias, so that each RCT was the unit of interest. </p> <p>We recorded the cumulative results of the searches and the selection process (i.e. including the prior version of this reviewÂ <a href="./references#CD012144-bbs2-0066" title="PerryLA , BergeE , BowditchJ , ForfangE , RÃ¸nningOM , HankeyGJ , VillanuevaE , Al-Shahi SalmanR . Antithrombotic treatment after stroke due to intracerebral haemorrhage. Cochrane Database of Systematic Reviews2017, Issue 5. Art. No: CD012144. [CENTRAL: CD012144] [DOI: 10.1002/14651858.CD012144.pub2] [PMID: 28540976]">Perry 2017</a>) and completed a flow diagram (<a href="#CD012144-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012144-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of study screening, eligibility assessment and inclusion" data-id="CD012144-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of study screening, eligibility assessment and inclusion</p> </div> </div> </div> </section> <section id="CD012144-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We created and independently completed an electronic data collection form in Microsoft Word (which had been piloted and used for the prior version of this review) for each included RCT. Two review authors (CC and AC) extracted data from included studies independently on methods, risk of bias, participant characteristics, intervention, comparator, and outcomes. We extracted outcome event frequencies without the need for transformation. Another review author checked all data extraction, queried errors, and agreed the final results in discussion with CC and AC. </p> <p>We sought and obtained unpublished data from one RCT (<a href="./references#CD012144-bbs2-0003" title="ShoamaneshA , SharmaM , DowlatshahiD , PikulaA , SmithEE , GladstoneDJ , et al. Non-vitamin K oral anticoagulants in intracerebral hemorrhage survivors with atrial fibrillation: primary results of the NASPAF-ICH randomized trial. In: International Stroke Conference, Session A28 - Late-Breaking Science Oral Abstracts II. Los Angeles, 2020. [CLINICALTRIALS.GOV: NCT02998905]">NASPAFâICH 2020</a>). We sought the data on a subgroup of participants with prior ICH from another RCT (<a href="./references#CD012144-bbs2-0020" title="OkumuraK , AkaoM , YoshidaT , KawataM , YamashitaT , et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. New England Journal of Medicine2020;383:1735-45. [DOI: 10.1056/NEJMoa2012883]OkumuraK , LipG , AkaoM , TanizawaK , FukuzawaM , AbeK , et al. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: rationale and design of the ELDERCARE-AF study. American Heart Journal2017;194:99-106. [DOI: 10.1016/j.ahj.2017.08.017]">ELDERCAREâAF 2020</a>), but data sufficient for analysis were not provided by the study Sponsor via the <a href="https://vivli.org/" target="_blank">Vivli data sharing platform</a> in time for inclusion in this review update. </p> </section> <section id="CD012144-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (AC and CC) assessed risks of bias for each study independently using the RoB 1 tool and the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012144-bbs2-0048" title="HigginsJP , Green S (editors)Â . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). Another review author reviewed all classifications, and achieved consensus via discussion. We assessed the risks of bias according to the following domains. </p> <p> <ul id="CD012144-list-0004"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other potential bias</p> </li> </ul> </p> <p>We graded the risk of bias for each domain as high, low or unclear and provide information from the study report, together with a justification for our judgement, in the risk of bias tables. </p> </section> <section id="CD012144-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We converted categorical data using numeric frequencies of outcomes and group sizes to estimates of effect using the risk ratio (RR), without adjustment. </p> </section> <section id="CD012144-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <section id="CD012144-sec-0032"> <h5 class="title">Repeated observations on participants</h5> <p>We planned to analyse functional and cognitive status at end of followâup or a period of followâup available for all RCTs being pooled, and not to use repeat observations during followâup. If one RCT (or only a few RCTs) had a much longer period of followâup than the majority of RCTs (e.g. two years compared with six months in the majority of trials) we intended to perform a sensitivity analysis using the sixâmonth observations from all RCTs. </p> </section> <section id="CD012144-sec-0033"> <h5 class="title">Events that may recur</h5> <p>We analysed the first event in all participants, and not later events.</p> </section> <section id="CD012144-sec-0034"> <h5 class="title">Multiple intervention groups</h5> <p>Where a RCT contained multiple treatment groups that were all compared with just one control group, we intended to ensure that the control group was shared between the multiple treatment groups by dividing it into the appropriate number of subgroups and conducting separate, independent comparisons. </p> </section> </section> <section id="CD012144-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We intended to contact RCT authors for unpublished data if relevant data were missing. If only a minority (less than half) of data were missing, we planned to ignore the missing data and perform a 'complete set analysis'. If more substantial amounts of data were missing, and there was a chance that data were not missing at random, we planned to perform sensitivity analyses assuming both a bestâcase and a worstâcase scenario, or apply statistical imputation or models, or both, to account for the missing data. A bestâcase scenario meant that we assumed that all missing data in the intervention group represent good outcomes and all missing data in the control group represent poor outcomes. A worstâcase scenario meant that we assumed that all missing data in the intervention group represent poor outcomes and all missing data in the control group represent good outcomes. </p> </section> <section id="CD012144-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We investigated heterogeneity between included RCTs using the I<sup>2</sup> statistic. We interpreted this value using the guide provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012144-bbs2-0040" title="DeeksJJ , HigginsJP , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>): </p> <p> <ul id="CD012144-list-0005"> <li> <p>0% to 74%: inconsiderable heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ul> </p> <p>If we observed considerable heterogeneity in our data, we intended to use sensitivity analysis to elucidate which factors might explain the heterogeneity. </p> </section> <section id="CD012144-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We included all published and unpublished data and secondary publications from RCTs. If we had included a sufficient number of RCTs (more than 10), we planned to assess the likelihood of reporting biases through the use of a funnel plot. </p> </section> <section id="CD012144-sec-0038"> <h4 class="title">Data synthesis</h4> <p>We included RCTs regardless of their risk of bias. If RCTs were sufficiently similar, we planned to conduct a metaâanalysis by pooling the appropriate data using RevMan Web (<a href="./references#CD012144-bbs2-0059" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). We calculated the RR for each outcome from data extracted from included RCTs using a fixedâeffect model, or a randomâeffects model if there was considerable qualitative or quantitative heterogeneity (I<sup>2</sup> â¥ 75%). </p> </section> <section id="CD012144-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We preâspecified the following subgroup analyses, which could modify the effects of antithrombotic drugs on ischaemic or haemorrhagic clinical outcome events. </p> <p> <ul id="CD012144-list-0006"> <li> <p>Participants</p> <ul id="CD012144-list-0007"> <li> <p>age</p> </li> <li> <p>sex</p> </li> <li> <p>stroke severity</p> </li> </ul> </li> <li> <p>Different classes of antithrombotic drugs (antiplatelet versus anticoagulant)</p> </li> <li> <p>Different intensities of antithrombotic treatment (low dose versus high dose)</p> </li> <li> <p>Different times of starting treatment (e.g. within one month of ICH versus later, or within 10 to 30 weeks or later) </p> </li> <li> <p>Participants who were on antithrombotic treatment before ICH (reâstarters) versus participants who were not receiving these treatments before ICH (starters) </p> </li> <li> <p>Different levels of risk for future ischaemic events (e.g. because of differences in age, sex, history of hypertension, history of AF (with further stratification by the CHA<sub>2</sub>DS<sub>2</sub>âVASc score)) </p> </li> <li> <p>Different levels of risk for future ICH (lobar versus nonâlobar ICH location)</p> </li> <li> <p>Biomarkers of bleeding or clotting risk on brain computed tomography (CT) or magnetic resonance imaging (MRI) (e.g. brain microbleeds on MRI) </p> </li> </ul> </p> </section> <section id="CD012144-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>If there was considerable qualitative or quantitative evidence of heterogeneity, we planned to use sensitivity analysis to investigate how the results differed when we excluded RCTs (e.g. those with a high risk of bias). We planned to perform other sensitivity analyses to explore reasons for heterogeneity, for example, where there is an active coâintervention other than an antithrombotic drug that is not balanced by the randomisation process. </p> </section> <section id="CD012144-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p><b>Outcome importance:</b> Given the number of preâspecified outcomes and comparisons in this review, we prioritised the five following clinically important outcomes for reporting in the Summary of findings tables and abstract: (1) MACE, (2) death, (3) major occlusive vascular events, (4) ICH, and (5) functional outcome. </p> <p><b>Summary of findings:</b> we created summary of findings tables using the GRADEpro Guideline Development Tool (<a href="./references#CD012144-bbs2-0046" title="GRADEpro Guideline Development Tool. McMaster University, 2015. Available from www.gradepro.org.">GRADEpro GDT</a>). </p> <p><b>Certainty of the evidence:</b> we classified the certainty of the evidence as being 'high', 'moderate', 'low', or 'very low', based on the presence and extent of the following five criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012144-bbs2-0062" title="SchÃ¼nemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , on behalf of the Cochrane GRADEing Methods Group. Chapter 14: Completing âSummary of findingsâ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">SchÃ¼nemann 2022</a>): </p> <p> <ul id="CD012144-list-0008"> <li> <p>limitations in the design and implementation of the contributing trials;</p> </li> <li> <p>indirectness of evidence;</p> </li> <li> <p>unexplained heterogeneity of results;</p> </li> <li> <p>imprecision of results;</p> </li> <li> <p>high probability of publication bias.</p> </li> </ul> </p> <p>We provided justification in the footnotes when we downgraded the certainty from 'high'.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012144-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012144-sec-0042"></div> <section id="CD012144-sec-0043"> <h3 class="title">Description of studies</h3> <p>After screening 10,635 records (<a href="#CD012144-fig-0001">Figure 1</a>), we excluded 10,586, assessed 49 fullâtext articles (20 of which were duplicate records), excluded 12 RCTs (<a href="./references#CD012144-bbs1-0002" title="">Excluded studies</a>), identified eight ongoing RCTs (<a href="./references#CD012144-bbs1-0004" title="">Ongoing studies</a>), and included nine RCTs in qualitative and quantitative syntheses (<a href="./references#CD012144-bbs1-0001" title="">Included studies</a>). </p> <section id="CD012144-sec-0044"> <h4 class="title">Results of the search</h4> <p>We included nine parallelâgroup RCTs in our review (<a href="./references#CD012144-bbs2-0001" title="SchreuderFH , vanNieuwenhuizenKM , HofmeijerJ , VermeerSE , KerkhoffH , ZockE , APACHE-AF Trial Investigators. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurology2021;20(11):907-16. [DOI: 10.1016/S1474-4422(21)00298-2] [PMID: 34687635]Van NieuwenhuizenKM , Van der WorpHB , AlgraA , KappelleLJ , RinkelGJ , Van GelderIC , et al. Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials2015;16:393. [DOI: 10.1186/s13063-015-0898-4]">APACHEâAF 2021</a>;Â <a href="./references#CD012144-bbs2-0002" title="DickmannU , VothE , SchichaH , HenzeT , PrangeH , EmrichD . Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral haemorrhage. Klinische Wochenschrift1988;66(23):1182-3. [DOI: 10.1007/BF01727666] [PMID: 3062268]">Dickmann 1988</a>;Â <a href="./references#CD012144-bbs2-0003" title="ShoamaneshA , SharmaM , DowlatshahiD , PikulaA , SmithEE , GladstoneDJ , et al. Non-vitamin K oral anticoagulants in intracerebral hemorrhage survivors with atrial fibrillation: primary results of the NASPAF-ICH randomized trial. In: International Stroke Conference, Session A28 - Late-Breaking Science Oral Abstracts II. Los Angeles, 2020. [CLINICALTRIALS.GOV: NCT02998905]">NASPAFâICH 2020</a>;Â <a href="./references#CD012144-bbs2-0004" title="OrkenDN , KenangilG , OzkurtH , GunerC , GundogduL , BasakM , et al. Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage. Neurologist2009;15(6):329-31. [DOI: 10.1097/NRL.0b013e3181a93bac] [PMID: 19901711]">Orken 2009</a>;Â <a href="./references#CD012144-bbs2-0005" title="KimBJ , KwonSU , ParkJH , KimYJ , HongKS , WongLK , PICASSO Investigators. Cilostazol versus aspirin in ischemic stroke patients with high-risk cerebral hemorrhage: subgroup analysis of the PICASSO Trial. Stroke2020;51(3):931-7. [CLINICALTRIALS.GOV: NCT01013532] [DOI: 10.1161/STROKEAHA.119.023855] [PMID: 31856691]KimBJ , LeeEJ , KwonSU , ParkJH , KimYJ , HongKS , PICASSO investigators. Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. Lancet Neurology2018;17(6):509-18. ">PICASSO subâgroup 2020</a>;Â <a href="./references#CD012144-bbs2-0006" title="PaciaroniM , AgnelliG , AlbertiA , BecattiniC , GuerciniF , MartiniG , et al. PREvention of VENous Thromboembolism In Hemorrhagic Stroke patients - PREVENTIHS Study: a randomized controlled trial and a systematic review and meta-analysis. European Neurology2020;83(6):566-75. [DOI: 10.1159/000511574] [PMID: 33190135]">PREVENTIHS 2020</a>;Â <a href="./references#CD012144-bbs2-0007" title="QianC , HuhtakangasJ , JuvelaS , BodeMK , TatlisumakT , SavolainenM , et al. Early vs. late enoxaparin for the prevention of venous thromboembolism in patients with ICH: a double blind placebo controlled multicenter study. Clinical Neurology and Neurosurgery2021;202:106534. [DOI: 10.1016/j.clineuro.2021.106534] [PMID: 33578226]">Qian 2021</a>;Â <a href="./references#CD012144-bbs2-0008" title="Al-Shahi SalmanR , DennisM , MurrayG , InnesK , DreverJ , DinsmoreL , et al. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. Trials2018;19:162. [DOI: 10.1186/s13063-018-2542-6]Al-Shahi SalmanR , MinksDP , MitraD , RodriguesMA , BhatnagarP , du PlessisJC , RESTART Collaboration. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology2019;18(7):643-52. [DOI: 10.1016/S1474-4422(19)30184-X] [PMID: 31129065]RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet2019;393(10191):2613-23. [DOI: 10.1016/S0140-6736(19)30840-2] [PMID: 31128924]">RESTART 2019</a>;Â <a href="./references#CD012144-bbs2-0009" title="SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurology2021;20(10):842-53. [DOI: 10.1016/S1474-4422(21)00264-7.] [PMID: 34487722]">SoSTART 2021</a>). </p> <p>We grouped these RCTs for description and analysis into four groups:</p> <p> <ul id="CD012144-list-0009"> <li> <p>shortâterm prophylactic dose anticoagulation (start versus avoid);</p> </li> <li> <p>longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid); </p> </li> <li> <p>longâterm antiplatelet therapy (start versus avoid);</p> </li> <li> <p>longâterm antiplatelet therapy (cilostazol versus aspirin).</p> </li> </ul> </p> </section> <section id="CD012144-sec-0045"> <h4 class="title">Shortâterm prophylactic dose anticoagulation (start versus avoid)</h4> <p><a href="./references#CD012144-bbs2-0002" title="DickmannU , VothE , SchichaH , HenzeT , PrangeH , EmrichD . Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral haemorrhage. Klinische Wochenschrift1988;66(23):1182-3. [DOI: 10.1007/BF01727666] [PMID: 3062268]">Dickmann 1988</a>Â took place in inpatient units in Germany. All 46 participants were administered 5000 units of heparin every eight hours, with the intervention group starting at day four after intracerebral haemorrhage (ICH) and the control group at day 10. Reâbleeding, thrombosis, pulmonary embolism and death were recorded until day 10. </p> <p><a href="./references#CD012144-bbs2-0004" title="OrkenDN , KenangilG , OzkurtH , GunerC , GundogduL , BasakM , et al. Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage. Neurologist2009;15(6):329-31. [DOI: 10.1097/NRL.0b013e3181a93bac] [PMID: 19901711]">Orken 2009</a>Â took place in Turkey and randomised 75 participants 48 hours after admission to 48 mg enoxaparin per day or compression stockings. Outcomes were measured on days seven and 21. </p> <p><a href="./references#CD012144-bbs2-0006" title="PaciaroniM , AgnelliG , AlbertiA , BecattiniC , GuerciniF , MartiniG , et al. PREvention of VENous Thromboembolism In Hemorrhagic Stroke patients - PREVENTIHS Study: a randomized controlled trial and a systematic review and meta-analysis. European Neurology2020;83(6):566-75. [DOI: 10.1159/000511574] [PMID: 33190135]">PREVENTIHS 2020</a>Â was conducted in Italian hospitals. The trial was discontinued because of low recruitment rates, but randomised 73 patients to 4000 units of enoxaparin or no treatment. Outcomes were measured up to day 90. </p> <p><a href="./references#CD012144-bbs2-0007" title="QianC , HuhtakangasJ , JuvelaS , BodeMK , TatlisumakT , SavolainenM , et al. Early vs. late enoxaparin for the prevention of venous thromboembolism in patients with ICH: a double blind placebo controlled multicenter study. Clinical Neurology and Neurosurgery2021;202:106534. [DOI: 10.1016/j.clineuro.2021.106534] [PMID: 33578226]">Qian 2021</a>Â took place in Helsinki and randomised 139 patients to the intervention of 2000 units of enoxaparin 12 or 24 hours after ICH, or to the placebo group who received saline injections. After the initial 72 hours, both groups received treatment with the same does of enoxaparin. Outcomes were measured up to day 90 after ICH. </p> </section> <section id="CD012144-sec-0046"> <h4 class="title">Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid) </h4> <p><a href="./references#CD012144-bbs2-0003" title="ShoamaneshA , SharmaM , DowlatshahiD , PikulaA , SmithEE , GladstoneDJ , et al. Non-vitamin K oral anticoagulants in intracerebral hemorrhage survivors with atrial fibrillation: primary results of the NASPAF-ICH randomized trial. In: International Stroke Conference, Session A28 - Late-Breaking Science Oral Abstracts II. Los Angeles, 2020. [CLINICALTRIALS.GOV: NCT02998905]">NASPAFâICH 2020</a>Â took place in Canada. It compared the effectiveness of nonâvitamin K antagonist oral anticoagulants (NOACs) to aspirin in 30 participants with prior ICH and AF randomised in a 2:1 ratio. Outcomes were measured between 10.5 months and 2.8 years after ICH. </p> <p><a href="./references#CD012144-bbs2-0009" title="SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurology2021;20(10):842-53. [DOI: 10.1016/S1474-4422(21)00264-7.] [PMID: 34487722]">SoSTART 2021</a>Â took place in the UK, included 203 participants who had atrial fibrillation (AF) and recent ICH, randomly assigned them to either start or avoid an oral anticoagulant (34 (33%) of the participants in the 'avoid oral anticoagulation' group took antiplatelet monotherapy), and identified outcomes for up to three years after randomisation. </p> <p><a href="./references#CD012144-bbs2-0001" title="SchreuderFH , vanNieuwenhuizenKM , HofmeijerJ , VermeerSE , KerkhoffH , ZockE , APACHE-AF Trial Investigators. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurology2021;20(11):907-16. [DOI: 10.1016/S1474-4422(21)00298-2] [PMID: 34687635]Van NieuwenhuizenKM , Van der WorpHB , AlgraA , KappelleLJ , RinkelGJ , Van GelderIC , et al. Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials2015;16:393. [DOI: 10.1186/s13063-015-0898-4]">APACHEâAF 2021</a>Â took place in the Netherlands, recruited 101 participants who had recent ICH and were already taking anticoagulation for AF, randomly assigned them to apixaban 5 mg twice daily or to avoid oral anticoagulation (26 (51%) of the participants in the 'avoid oral anticoagulation' group took antiplatelet therapy), and identified outcomes for up to three years after randomisation. </p> </section> <section id="CD012144-sec-0047"> <h4 class="title">Longâterm antiplatelet therapy (start versus avoid)</h4> <p><a href="./references#CD012144-bbs2-0008" title="Al-Shahi SalmanR , DennisM , MurrayG , InnesK , DreverJ , DinsmoreL , et al. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. Trials2018;19:162. [DOI: 10.1186/s13063-018-2542-6]Al-Shahi SalmanR , MinksDP , MitraD , RodriguesMA , BhatnagarP , du PlessisJC , RESTART Collaboration. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology2019;18(7):643-52. [DOI: 10.1016/S1474-4422(19)30184-X] [PMID: 31129065]RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet2019;393(10191):2613-23. [DOI: 10.1016/S0140-6736(19)30840-2] [PMID: 31128924]">RESTART 2019</a>Â took place in the UK and included 537 participants who had been taking an antithrombotic drug until the time of ICH, and randomised them to starting or avoiding antiplatelet therapy. Participants were followed up for a minimum of six months. </p> </section> <section id="CD012144-sec-0048"> <h4 class="title">Longâterm antiplatelet therapy (cilostazol versus aspirin)</h4> <p><a href="./references#CD012144-bbs2-0005" title="KimBJ , KwonSU , ParkJH , KimYJ , HongKS , WongLK , PICASSO Investigators. Cilostazol versus aspirin in ischemic stroke patients with high-risk cerebral hemorrhage: subgroup analysis of the PICASSO Trial. Stroke2020;51(3):931-7. [CLINICALTRIALS.GOV: NCT01013532] [DOI: 10.1161/STROKEAHA.119.023855] [PMID: 31856691]KimBJ , LeeEJ , KwonSU , ParkJH , KimYJ , HongKS , PICASSO investigators. Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. Lancet Neurology2018;17(6):509-18. ">PICASSO subâgroup 2020</a>Â was a separate report of a subgroup of a factorial trial which took place in 67 centres in Asian countries. The subgroup included 268 patients with history of ICH, randomised to cilostazol or aspirin either with or without probucol. </p> </section> <section id="CD012144-sec-0049"> <h4 class="title">Excluded studies</h4> <p><b>Excluded studies</b> </p> <p>We excluded 10 RCTs.</p> <p><a href="./references#CD012144-bbs2-0010" title="BoeerA , VothE , HenzeT , PrangeHW . Early heparin therapy in patients with spontaneous intracerebral haemorrhage. Journal of Neurology, Neurosurgery and Psychiatry1991;54(5):466-7. [DOI: 10.1136/jnnp.54.5.466]">Boeer 1991</a>Â was an extension phase ofÂ <a href="./references#CD012144-bbs2-0002" title="DickmannU , VothE , SchichaH , HenzeT , PrangeH , EmrichD . Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral haemorrhage. Klinische Wochenschrift1988;66(23):1182-3. [DOI: 10.1007/BF01727666] [PMID: 3062268]">Dickmann 1988</a>, but randomisation was not described. </p> <p><a href="./references#CD012144-bbs2-0011" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke; CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet1997;349(9066):1641-9. [DOI: 10.1016/S0140-6736(97)04010-5] [PMID: 9186381]">CAST 1997</a>Â andÂ <a href="./references#CD012144-bbs2-0014" title="International Stroke Trial Collaborative Group. The International Stoke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet1997;349(9065):1569-81. [DOI: 10.1016/S0140-6736(97)04011-7] [PMID: 9186381]">IST 1997</a>Â were two RCTs investigating the use of antiplatelet treatment after acute ischaemic stroke, and inadvertently included several hundred participants with ICH who were randomised before computed tomography (CT) had been performed to establish the pathological subtype of stroke. Data on the ICH subpopulation of these studies were reported in a systematic review (<a href="./references#CD012144-bbs2-0049" title="KeirSL , WardlawJM , SandercockPA , ChenZ . Antithrombotic therapy in patients with any form of intracranial haemorrhage: a systematic review of the available controlled studies. Cerebrovascular Diseases2002;14(3-4):197-206. [DOI: 10.1159/000065661]">Keir 2002</a>) and the individual patient data fromÂ <a href="./references#CD012144-bbs2-0014" title="International Stroke Trial Collaborative Group. The International Stoke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet1997;349(9065):1569-81. [DOI: 10.1016/S0140-6736(97)04011-7] [PMID: 9186381]">IST 1997</a>Â (<a href="./references#CD012144-bbs2-0061" title="SandercockPA , NiewadaM , CzlonkowskaA , the International Stroke Trial Collaborative Group. The International Stroke Trial database. Trials2011;12:101. [DOI: 10.1186/1745-6215-12-101]">Sandercock 2011</a>). These sources reported that this population included spontaneous ICH (52%) and haemorrhagic transformation of ischaemic stroke (48%), but unfortunately the chief investigator informed us that it would be impossible to isolate the participants with spontaneous ICH (<a href="./references#CD012144-bbs2-0014" title="International Stroke Trial Collaborative Group. The International Stoke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet1997;349(9065):1569-81. [DOI: 10.1016/S0140-6736(97)04011-7] [PMID: 9186381]">IST 1997</a>). </p> <p><a href="./references#CD012144-bbs2-0013" title="FronteraJA , JovineM , ZachV , GordonE . Safety of venous thromboembolism prophylaxis in intracranial hemorrhage patients with external ventricular drains. Stroke2014;45:236. ">Frontera 2014</a>Â  andÂ <a href="./references#CD012144-bbs2-0015" title="KuramatsuJB , HuttnerHB . Restarting therapeutic anticoagulation in patients with intracerebral hemorrhage and mechanical heart valves. Stroke2018;49 Suppl 1:Abstract 50. [DOI: 10.1161/str.49.suppl_1.50]">Kuramatsu 2018</a>Â were not randomised. </p> <p><a href="./references#CD012144-bbs2-0016" title="LiX , ZhaoshengS , ZhaoW , ZhangJ , ChenJ , LiY , et al. Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage. Journal of Neurosurgery2013;118:94-103. [DOI: 10.3171/2012.9.JNS112286]">Li 2013</a>Â assessed transfusion of frozen apheresis platelets (platelets collected by separation from whole blood) in patients with ICH and on aspirin. </p> <p><a href="./references#CD012144-bbs2-0018" title="VenturelliPA , WangX , ArimaH , HeeleyE , DelcourtC , LavadosP , et al. Safety of prophylactic heparin in acute intracerebral haemorrhage: post-hoc analysis of the INTERACT2 study. International Journal of Stroke2014;9 Suppl 1:38. ">Venturelli 2014</a>Â was a postâhoc analysis of a RCT in which antithrombotic treatment was not randomly assigned, making this analysis observational in nature. </p> <p><a href="./references#CD012144-bbs2-0019" title="YanL , LiYD , LiYH , LiMH , ZhaoJG , ChenSW . Outcomes of antiplatelet therapy for haemorrhage patients after thrombolysis: a prospective study based on susceptibility-weighted imaging. La Radiologica Medica2014;119(3):175-82. [DOI: 10.1007/s11547-013-0328-1]">Yan 2014</a>Â included a population of patients with and without cerebral microbleeds after acute ischaemic stroke, but not ICH. </p> <p><a href="./references#CD012144-bbs2-0017" title="Al-Shahi SalmanR , DennisMS , SandercockPA , SudlowCLM , WardlawJM , WhiteleyWN , RESTART Collaboration. Effects of antiplatelet therapy after stroke caused by intracerebral hemorrhage: extended follow-up of the RESTART randomized clinical trial. JAMA Neurology2021;78(10):1179-86. [DOI: 10.1001/jamaneurol.2021.2956]">RESTART extended followâup</a>Â was a twoâyear extension ofÂ <a href="./references#CD012144-bbs2-0008" title="Al-Shahi SalmanR , DennisM , MurrayG , InnesK , DreverJ , DinsmoreL , et al. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. Trials2018;19:162. [DOI: 10.1186/s13063-018-2542-6]Al-Shahi SalmanR , MinksDP , MitraD , RodriguesMA , BhatnagarP , du PlessisJC , RESTART Collaboration. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology2019;18(7):643-52. [DOI: 10.1016/S1474-4422(19)30184-X] [PMID: 31129065]RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet2019;393(10191):2613-23. [DOI: 10.1016/S0140-6736(19)30840-2] [PMID: 31128924]">RESTART 2019</a>, but participants and their primary care practitioners had been told the results ofÂ <a href="./references#CD012144-bbs2-0008" title="Al-Shahi SalmanR , DennisM , MurrayG , InnesK , DreverJ , DinsmoreL , et al. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. Trials2018;19:162. [DOI: 10.1186/s13063-018-2542-6]Al-Shahi SalmanR , MinksDP , MitraD , RodriguesMA , BhatnagarP , du PlessisJC , RESTART Collaboration. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology2019;18(7):643-52. [DOI: 10.1016/S1474-4422(19)30184-X] [PMID: 31129065]RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet2019;393(10191):2613-23. [DOI: 10.1016/S0140-6736(19)30840-2] [PMID: 31128924]">RESTART 2019</a>, which put the extended followâup at higher risk of bias than the main report, so we includedÂ <a href="./references#CD012144-bbs2-0008" title="Al-Shahi SalmanR , DennisM , MurrayG , InnesK , DreverJ , DinsmoreL , et al. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. Trials2018;19:162. [DOI: 10.1186/s13063-018-2542-6]Al-Shahi SalmanR , MinksDP , MitraD , RodriguesMA , BhatnagarP , du PlessisJC , RESTART Collaboration. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology2019;18(7):643-52. [DOI: 10.1016/S1474-4422(19)30184-X] [PMID: 31129065]RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet2019;393(10191):2613-23. [DOI: 10.1016/S0140-6736(19)30840-2] [PMID: 31128924]">RESTART 2019</a>Â and excludedÂ <a href="./references#CD012144-bbs2-0017" title="Al-Shahi SalmanR , DennisMS , SandercockPA , SudlowCLM , WardlawJM , WhiteleyWN , RESTART Collaboration. Effects of antiplatelet therapy after stroke caused by intracerebral hemorrhage: extended follow-up of the RESTART randomized clinical trial. JAMA Neurology2021;78(10):1179-86. [DOI: 10.1001/jamaneurol.2021.2956]">RESTART extended followâup</a>. </p> <p><a href="./references#CD012144-bbs2-0012" title="ChiCTR2000040166. A multi-center, randomized, double-blind, placebo-controlled clinical study of SXHYXN combined with ZLHXTY in the treatment of cerebral hemorrhage. http://www.chictr.org.cn/showprojen.aspx?proj=63798 (first received 23 November 2020). [CHICTR: 2000040166]">ChiCTR2000040166</a>Â used two traditional Chinese medicines which are not proven to have antithrombotic effects and therefore did not meet the criteria for the review. </p> <p><b>Studies awaiting classification</b> </p> <p><a href="./references#CD012144-bbs2-0020" title="OkumuraK , AkaoM , YoshidaT , KawataM , YamashitaT , et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. New England Journal of Medicine2020;383:1735-45. [DOI: 10.1056/NEJMoa2012883]OkumuraK , LipG , AkaoM , TanizawaK , FukuzawaM , AbeK , et al. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: rationale and design of the ELDERCARE-AF study. American Heart Journal2017;194:99-106. [DOI: 10.1016/j.ahj.2017.08.017]">ELDERCAREâAF 2020</a>Â andÂ <a href="./references#CD012144-bbs2-0021" title="OsmancikP , HermanD , NeuzilP , HalaP , TaborskyM , KalaP , et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. Journal of the American College of Cardiology2020;75(25):3122â35. [DOI: 10.1016/j.jacc.2020.04.067]">PRAGUEâ17 2020</a>Â were suitable for inclusion in our review,Â butÂ <a href="./references#CD012144-bbs2-0020" title="OkumuraK , AkaoM , YoshidaT , KawataM , YamashitaT , et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. New England Journal of Medicine2020;383:1735-45. [DOI: 10.1056/NEJMoa2012883]OkumuraK , LipG , AkaoM , TanizawaK , FukuzawaM , AbeK , et al. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: rationale and design of the ELDERCARE-AF study. American Heart Journal2017;194:99-106. [DOI: 10.1016/j.ahj.2017.08.017]">ELDERCAREâAF 2020</a>Â did not provide data that were sufficient for accurate analysis and the corresponding author ofÂ <a href="./references#CD012144-bbs2-0021" title="OsmancikP , HermanD , NeuzilP , HalaP , TaborskyM , KalaP , et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. Journal of the American College of Cardiology2020;75(25):3122â35. [DOI: 10.1016/j.jacc.2020.04.067]">PRAGUEâ17 2020</a>Â was unable to provide the data for the subgroup of patients with prior ICH in time for inclusion in this review, so these studies are categorised asÂ <a href="./references#CD012144-bbs1-0003" title="">Studies awaiting classification</a>. </p> </section> </section> <section id="CD012144-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed all included RCTs for their risk of bias (<a href="#CD012144-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD012144-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD012144-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD012144-sec-0051"> <h4 class="title">Allocation</h4> <p>Sixtyâseven per cent of included RCTs were at low risk of bias in random sequence generation. </p> <p>Sixtyâseven per cent of included RCTs were at low risk of bias in allocation concealment.</p> </section> <section id="CD012144-sec-0052"> <h4 class="title">Blinding</h4> <p>Twentyâtwo per cent of included RCTs were at low risk of performance bias due to blinding of participants and personnel. </p> <p>Seventyâeight per cent of included RCTs were at low risk of detection bias in blinding of outcome assessment. </p> </section> <section id="CD012144-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p>Eightyânine per cent of included RCTs were at low risk of attrition bias.</p> </section> <section id="CD012144-sec-0054"> <h4 class="title">Selective reporting</h4> <p>Seventyâeight per cent of included RCTs were at low risk of reporting bias.</p> </section> <section id="CD012144-sec-0055"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify any other major sources of bias.</p> </section> </section> <section id="CD012144-sec-0056"> <h3 class="title" id="CD012144-sec-0056">Effects of interventions</h3> <p>See: <a href="./full#CD012144-tbl-0001"><b>Summary of findings 1</b> Summary of findings table â Starting shortâterm prophylactic dose anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage</a>; <a href="./full#CD012144-tbl-0002"><b>Summary of findings 2</b> Summary of findings table â Starting longâterm therapeutic dose oral anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage with atrial fibrillation</a>; <a href="./full#CD012144-tbl-0003"><b>Summary of findings 3</b> Summary of findings table â Starting longâterm oral antiplatelet therapy compared to avoiding antithrombotic therapy for survivors of stroke due to intracerebral haemorrhage</a>; <a href="./full#CD012144-tbl-0004"><b>Summary of findings 4</b> Summary of findings table â Cilostazol compared to aspirin for adults within 180 days of nonâcardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral haemorrhage</a> </p> <section id="CD012144-sec-0057"> <h4 class="title">Shortâterm prophylactic dose anticoagulation (start versus avoid)</h4> <p>We included four RCTs, all of which compared a parenteral anticoagulant to no treatment, although there was considerable qualitative heterogeneity between the RCTs' interventions, comparators, and timing of assessment, so we used randomâeffects models to pool their effect estimates (<a href="./references#CD012144-bbs2-0002" title="DickmannU , VothE , SchichaH , HenzeT , PrangeH , EmrichD . Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral haemorrhage. Klinische Wochenschrift1988;66(23):1182-3. [DOI: 10.1007/BF01727666] [PMID: 3062268]">Dickmann 1988</a>;Â <a href="./references#CD012144-bbs2-0004" title="OrkenDN , KenangilG , OzkurtH , GunerC , GundogduL , BasakM , et al. Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage. Neurologist2009;15(6):329-31. [DOI: 10.1097/NRL.0b013e3181a93bac] [PMID: 19901711]">Orken 2009</a>;Â <a href="./references#CD012144-bbs2-0006" title="PaciaroniM , AgnelliG , AlbertiA , BecattiniC , GuerciniF , MartiniG , et al. PREvention of VENous Thromboembolism In Hemorrhagic Stroke patients - PREVENTIHS Study: a randomized controlled trial and a systematic review and meta-analysis. European Neurology2020;83(6):566-75. [DOI: 10.1159/000511574] [PMID: 33190135]">PREVENTIHS 2020</a>;Â <a href="./references#CD012144-bbs2-0007" title="QianC , HuhtakangasJ , JuvelaS , BodeMK , TatlisumakT , SavolainenM , et al. Early vs. late enoxaparin for the prevention of venous thromboembolism in patients with ICH: a double blind placebo controlled multicenter study. Clinical Neurology and Neurosurgery2021;202:106534. [DOI: 10.1016/j.clineuro.2021.106534] [PMID: 33578226]">Qian 2021</a>). We present our summary of findings inÂ <a href="./full#CD012144-tbl-0001">summary of findings Table 1</a>. We did not need to make postâhoc decisions that could have led to selective outcome reporting. </p> <section id="CD012144-sec-0058"> <h5 class="title">Primary outcome</h5> <p>We were unable to extract data on our primary outcome and some secondary outcomes (ischaemic stroke, myocardial infarction, vascular death, and cognitive status) from any of the RCTs, and we did not succeed in obtaining these outcomes from the corresponding authors. </p> </section> <section id="CD012144-sec-0059"> <h5 class="title">Secondary outcomes</h5> <p>We did not find significant differences with starting versus avoiding shortâterm prophylactic dose anticoagulation in the secondary outcomes that were reported. </p> <p> <ul id="CD012144-list-0010"> <li> <p>Death of any cause (23/132 versus 22/126; risk ratio (RR) 1.00, 95% confidence interval (CI) 0.59 to 1.70, P = 1.00; 3 published RCTs; 258 participants; very lowâcertainty evidence;Â <a href="./references#CD012144-fig-0003" title="">Analysis 1.1</a>). </p> </li> <li> <p>We considered the relevant clinically important composite of major occlusive events for this treatment comparison to be venous thromboembolism (21/171 versus 23/162; RR 0.84, 95% CI 0.51 to 1.37, P = 0.49; 4 published RCTs; 333 participants; very lowâcertainty evidence;Â <a href="./references#CD012144-fig-0006" title="">Analysis 1.4</a>). </p> </li> <li> <p>Intracerebral haemorrhage (ICH) (1/61 versus 6/58; RR 0.24, 95% CI 0.04 to 1.38, P = 0.11; 2 published RCTs; 119 participants; very lowâcertainty evidence;Â <a href="./references#CD012144-fig-0007" title="">Analysis 1.5</a>). </p> </li> <li> <p>Functional independence, graded 0â2 on the modified Rankin Scale (mRS) score (11/38 versus 5/35; RR 2.03, 95% CI 0.78 to 5.25, P = 0.15; 1 published RCT; 73 participants; very lowâcertainty evidence;Â <a href="./references#CD012144-fig-0010" title="">Analysis 1.8</a>). </p> </li> <li> <p>ICH growth (8/110 versus 8/104; RR 0.96, 95% CI 0.38 to 2.41, P = 0.93; 2 published RCTs; 214 participants;Â <a href="./references#CD012144-fig-0009" title="">Analysis 1.7</a>). </p> </li> <li> <p>Major extracerebral haemorrhage (1/148 versus 0/139; RR 2.77, 95% CI 0.12 to 65.82, P = 0.53; 3 published RCTs; 287 participants;Â <a href="./references#CD012144-fig-0008" title="">Analysis 1.6</a>). </p> </li> <li> <p>Deep vein thrombosis (13/133 versus 12/127; RR 0.96, 95% CI 0.49 to 1.86, P = 0.9; 3 published RCTs; 260 participants;Â <a href="./references#CD012144-fig-0004" title="">Analysis 1.2</a>). </p> </li> <li> <p>Pulmonary embolism (6/171 versus 13/162; RR 0.50, 95% CI 0.22 to 1.14, P = 0.1; 4 published RCTs; 333 participants;Â <a href="./references#CD012144-fig-0005" title="">Analysis 1.3</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012144-sec-0060"> <h4 class="title">Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid) </h4> <p>We included three RCTs, all of which compared longâterm therapeutic dose of an oral anticoagulant (almost exclusively direct oral anticoagulants (DOACs)) to avoidance of anticoagulation (in which some patients took longâterm antiplatelet therapy and others avoided all antithrombotic drugs) (<a href="./references#CD012144-bbs2-0001" title="SchreuderFH , vanNieuwenhuizenKM , HofmeijerJ , VermeerSE , KerkhoffH , ZockE , APACHE-AF Trial Investigators. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurology2021;20(11):907-16. [DOI: 10.1016/S1474-4422(21)00298-2] [PMID: 34687635]Van NieuwenhuizenKM , Van der WorpHB , AlgraA , KappelleLJ , RinkelGJ , Van GelderIC , et al. Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials2015;16:393. [DOI: 10.1186/s13063-015-0898-4]">APACHEâAF 2021</a>;Â <a href="./references#CD012144-bbs2-0003" title="ShoamaneshA , SharmaM , DowlatshahiD , PikulaA , SmithEE , GladstoneDJ , et al. Non-vitamin K oral anticoagulants in intracerebral hemorrhage survivors with atrial fibrillation: primary results of the NASPAF-ICH randomized trial. In: International Stroke Conference, Session A28 - Late-Breaking Science Oral Abstracts II. Los Angeles, 2020. [CLINICALTRIALS.GOV: NCT02998905]">NASPAFâICH 2020</a>;Â <a href="./references#CD012144-bbs2-0009" title="SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurology2021;20(10):842-53. [DOI: 10.1016/S1474-4422(21)00264-7.] [PMID: 34487722]">SoSTART 2021</a>). We present our summary of findings inÂ <a href="./full#CD012144-tbl-0002">summary of findings Table 2</a>. We did not need to make postâhoc decisions that could have led to selective outcome reporting. </p> <section id="CD012144-sec-0061"> <h5 class="title">Primary outcome</h5> <p>We found a significant reduction in the composite primary outcome of Â major adverse cardiovascular events (MACE) with starting versus avoiding longâterm oral anticoagulation (26/172 versus 42/162; RR 0.61, 95% CI 0.40 to 0.94, P = 0.02; 2 published and 1 unpublished RCTs; 334 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0011" title="">Analysis 2.1</a>). </p> </section> <section id="CD012144-sec-0062"> <h5 class="title">Secondary outcomes</h5> <p>The effects of starting versus avoiding longâterm oral anticoagulation for atrial fibrillation on secondary outcomes were as follows. </p> <p> <ul id="CD012144-list-0011"> <li> <p>Death (24/172 versus 22/162; RR 1.05, 95% CI 0.62 to 1.78, P = 0.86; 2 published and 1 unpublished RCTs; 334 participants; moderateâcertainty evidence;<b>Â </b><a href="./references#CD012144-fig-0012" title="">Analysis 2.2</a>). </p> </li> <li> <p>Major occlusive vascular events (9/172 versus 34/162; RR 0.27, 95% CI 0.14 to 0.53, P = 0.0002; 3 RCTs; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0015" title="">Analysis 2.5</a>). </p> </li> <li> <p>Intracranial haemorrhage (12/172 versus 5/162; RR 2.43, 95% CI 0.88 to 6.73, P = 0.09; 2 published and 1 unpublished RCTs; 334 participants; moderateâcertainty evidence;<b>Â </b><a href="./references#CD012144-fig-0016" title="">Analysis 2.6</a>). </p> </li> <li> <p>Functional independence, graded 0â2 on the modified Rankin Scale (mRS) score (11/38 versus 5/35; RR 0.98, 95% CI 0.78 to 1.24, P = 0.87; 2 published RCTs; 288 participants; very lowâcertainty evidence;Â <a href="./references#CD012144-fig-0019" title="">Analysis 2.9</a>). </p> </li> <li> <p>Myocardial infarction (0/172 versus 4/162; RR 0.20, 95% CI 0.02 to 1.71, P =0.14; 2 published and 1 unpublished RCTs; 334 participants; moderateâcertainty evidence;<b>Â </b><a href="./references#CD012144-fig-0014" title="">Analysis 2.4</a>). </p> </li> <li> <p>Major extracerebral haemorrhage (2/172 versus 3/162; RR 0.58, 95 %CI 0.13 to 2.57, P = 0.47; 2 published and 1 unpublished RCTs; 334 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0017" title="">Analysis 2.7</a>). </p> </li> <li> <p>Ischaemic stroke (9/172 versus 26/162; RR 0.35, 95% CI 0.17 to 0.71; P = 0.004; 2 published and 1 unpublished RCTs; 334 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0013" title="">Analysis 2.3</a>). </p> </li> <li> <p>Vascular death (13/172 versus 9/162; RR 1.47, 95% CI 0.65 to 3.32, P = 0.36;Â  2 published and 1 unpublished RCTs; 334 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0018" title="">Analysis 2.8</a>). </p> </li> <li> <p>Modified Rankin Scale score 0 to 2 at one year (69/143 versus 71/145; RR 0.98, 95% CI 0.78 to 1.24, P = 0.87; 2 published RCTs; 288 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0019" title="">Analysis 2.9</a>). </p> </li> <li> <p>Any stroke (21/172 versus 30/162; RR 0.70, 95% CI 0.42 to 1.15, P = 0.16; 2 published and 1 unpublished RCTs; 334 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0020" title="">Analysis 2.10</a>). </p> </li> <li> <p>Any stroke or vascular death (25/151 versus 35/153; RR 0.72, 95% CI 0.46 to 1.15, P = 0.17; 2 published RCTs; 304 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0021" title="">Analysis 2.11</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012144-sec-0063"> <h4 class="title">Longâterm antiplatelet therapy (start versus avoid)</h4> <p>WeÂ included one RCTÂ which compared longâterm antiplatelet therapy (with aspirin Â± dipyridamole Â± clopidogrel) to avoidance of antithrombotic therapy in 537 participants, one of whom withdrew from followâup (<a href="./references#CD012144-bbs2-0008" title="Al-Shahi SalmanR , DennisM , MurrayG , InnesK , DreverJ , DinsmoreL , et al. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. Trials2018;19:162. [DOI: 10.1186/s13063-018-2542-6]Al-Shahi SalmanR , MinksDP , MitraD , RodriguesMA , BhatnagarP , du PlessisJC , RESTART Collaboration. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology2019;18(7):643-52. [DOI: 10.1016/S1474-4422(19)30184-X] [PMID: 31129065]RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet2019;393(10191):2613-23. [DOI: 10.1016/S0140-6736(19)30840-2] [PMID: 31128924]">RESTART 2019</a>). We present our summary of findings inÂ <a href="./full#CD012144-tbl-0003">summary of findings Table 3</a>. We did not need to make postâhoc decisions that could have led to selective outcome reporting. </p> <section id="CD012144-sec-0064"> <h5 class="title">Primary outcome</h5> <p>We did not find a significant difference in the composite primary outcome of MACE with starting versus avoiding longâterm oral antiplatelet therapy (54/268 versus 61/268; RR 0.89, 95% CI 0.64 to 1.22, P = 0.46; 1 published RCT; 536 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0022" title="">Analysis 3.1</a>). </p> </section> <section id="CD012144-sec-0065"> <h5 class="title">Secondary outcomes</h5> <p>The effects of starting versus avoiding longâterm oral antiplatelet therapy on secondary outcomes were as follows. </p> <p> <ul id="CD012144-list-0012"> <li> <p>Death (54/268 versus 50/268; RR 1.08, 95% CI 0.76 to 1.53, P = 0.66; 1 published RCT; 536 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0023" title="">Analysis 3.2</a>). </p> </li> <li> <p>All major occlusive vascular events (39/268 versus 38/268; RR 1.03, 95% CI 0.68 to 1.55, P = 0.90; 1 published RCT; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0026" title="">Analysis 3.5</a>). </p> </li> <li> <p>ICH (12/268 versus 23/268; RR 0.52, 95% CI 0.27 to 1.03, P = 0.06; 1 published RCT; 536 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0027" title="">Analysis 3.6</a>). </p> </li> <li> <p>Functional independence, graded 0â2 on the modified Rankin Scale (mRS) score (95/230 versus 100/231; RR 0.95, 95% CI 0.77 to 1.18, P = 0.67; 1 RCT; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0030" title="">Analysis 3.9</a>). </p> </li> <li> <p>Major vascular events as defined by the Antithrombotic Trialistsâ Collaboration (45/268 versus 65/268; RR 0.69, 95% CI 0.49 to 0.97; P = 0.03; 1 published RCT; 536 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0033" title="">Analysis 3.12</a>). </p> </li> <li> <p>Major extracerebral haemorrhage (8/268 versus 3/268; RR 2.67, 95% CI 0.72 to 9.94, P = 0.14; 1 published RCT; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0028" title="">Analysis 3.7</a>). </p> </li> <li> <p>Ischaemic stroke (19/268 versus 27/268; RR 0.70, 95% CI 0.40 to 1.23, P = 0.22; 1 published RCT; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0024" title="">Analysis 3.3</a>). </p> </li> <li> <p>Myocardial infarction (5/268 versus 8/268; RR 0.63, 95% CI 0.21 to 1.89, P = 0.40; 1 published RCT; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0025" title="">Analysis 3.4</a>). </p> </li> <li> <p>Deep vein thrombosis (6/268 versus 2/268; RR 3.00 (95% CI 0.61 to 14.73, P = 0.18; 1 published RCT; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0031" title="">Analysis 3.10</a>). </p> </li> <li> <p>Vascular death (18/268 versus 27/268; RR 0.67 (95% CI 0.38 to 1.18, P = 0.16; 1 published RCT; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0029" title="">Analysis 3.8</a>). </p> </li> <li> <p>All major haemorrhagic events (18/268 versus 25/268; RR 0.72 (95% CI 0.40 to 1.29, P = 0.27; 1 published RCT; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0032" title="">Analysis 3.11</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012144-sec-0066"> <h4 class="title">Longâterm antiplatelet therapy (cilostazol versus aspirin)</h4> <p>We included a subgroup of one RCT including adults within 180 days of nonâcardioembolic ischaemic stroke or transient ischaemic attack and a high risk of bleeding (<a href="./references#CD012144-bbs2-0057" title="KimBJ , LeeEJ , KwonSU , ParkJH , KimYJ , HongKS , PICASSO investigators. Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. Lancet Neurology2018;17:509-18. [DOI: 10.1016/S1474-4422(18)30128-5]">PICASSO 2018</a>), in which the reporting of outcomes for 288 participants with prior ICH was separate from the other participants (<a href="./references#CD012144-bbs2-0005" title="KimBJ , KwonSU , ParkJH , KimYJ , HongKS , WongLK , PICASSO Investigators. Cilostazol versus aspirin in ischemic stroke patients with high-risk cerebral hemorrhage: subgroup analysis of the PICASSO Trial. Stroke2020;51(3):931-7. [CLINICALTRIALS.GOV: NCT01013532] [DOI: 10.1161/STROKEAHA.119.023855] [PMID: 31856691]KimBJ , LeeEJ , KwonSU , ParkJH , KimYJ , HongKS , PICASSO investigators. Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. Lancet Neurology2018;17(6):509-18. ">PICASSO subâgroup 2020</a>). We present our summary of findings for this subgroup inÂ <a href="./full#CD012144-tbl-0004">summary of findings Table 4</a>. We did not need to make postâhoc decisions that could have led to selective outcome reporting. </p> <section id="CD012144-sec-0067"> <h5 class="title">Primary outcome</h5> <p>We did not find a significant difference in the composite primary outcome of MACE with longâterm cilostazol versus aspirin (22/142 versus 17/146; RR 1.33, 95% CI 0.74 to 2.40), P = 0.34; 1 published RCT; 288 participants; lowâcertainty evidence;Â <a href="./references#CD012144-fig-0034" title="">Analysis 4.1</a>). </p> </section> <section id="CD012144-sec-0068"> <h5 class="title">Secondary outcomes</h5> <p>The effects of longâterm cilostazol versus aspirin on secondary outcomes were as follows.Â </p> <p> <ul id="CD012144-list-0013"> <li> <p>Death (8/142 versus 5/146; RR 1.65, 95% CI 0.55 to 4.91, P = 0.37; 1 published RCT; 288 participants; lowâcertainty evidence;Â <a href="./references#CD012144-fig-0035" title="">Analysis 4.2</a>). </p> </li> <li> <p>ICH (5/142 versus 4/146; RR 1.29, 95% CI 0.35 to 4.69, P = 0.70; 1 published RCT; 288 participants; lowâcertainty evidence;Â <a href="./references#CD012144-fig-0038" title="">Analysis 4.5</a>). </p> </li> <li> <p>All major occlusive vascular events were not reported.</p> </li> <li> <p>Functional status was not reported.</p> </li> <li> <p>Ischaemic stroke (12/142 versus 13/146; RR 0.95, 95% CI 0.45 to 2.01, P = 0.89; 1 published RCT; 288 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0036" title="">Analysis 4.3</a>). </p> </li> <li> <p>Myocardial infarction (5/142 versus 0/146; RR 11.31, 95% CI 0.63 to 202.63, P = 0.10; 1 published RCT; 288 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0037" title="">Analysis 4.4</a>). </p> </li> <li> <p>Vascular death (3/142 versus 0/146; RR 7.35, 95% CI 0.38 to 143.61, P = 0.19; 1 published RCT; 288 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0039" title="">Analysis 4.6</a>). </p> </li> <li> <p>Any stroke (16/142 versus 17/146; RR 0.97, 95% CI 0.51 to 1.84, P = 0.92; 1 published RCT; 288 participants; moderateâcertainty evidence;Â <a href="./references#CD012144-fig-0040" title="">Analysis 4.7</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012144-sec-0069"> <h4 class="title">Subgroup analyses</h4> <p>We did not extract subgroup data from comparisons addressed by only one RCT, each of which was underâpowered to estimate overall effects. Subgroups of interest were not reported for RCTs of shortâterm prophylactic dose anticoagulation. Two RCTs of longâterm therapeutic dose anticoagulation for AF reported data in subgroups (<a href="./references#CD012144-bbs2-0001" title="SchreuderFH , vanNieuwenhuizenKM , HofmeijerJ , VermeerSE , KerkhoffH , ZockE , APACHE-AF Trial Investigators. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurology2021;20(11):907-16. [DOI: 10.1016/S1474-4422(21)00298-2] [PMID: 34687635]Van NieuwenhuizenKM , Van der WorpHB , AlgraA , KappelleLJ , RinkelGJ , Van GelderIC , et al. Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials2015;16:393. [DOI: 10.1186/s13063-015-0898-4]">APACHEâAF 2021</a>;Â <a href="./references#CD012144-bbs2-0009" title="SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurology2021;20(10):842-53. [DOI: 10.1016/S1474-4422(21)00264-7.] [PMID: 34487722]">SoSTART 2021</a>); however, the classifications of the subgroups and outcomes reported did not permit pooling of data for subgroup analysis. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012144-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012144-sec-0070"></div> <p>In this updated review, we found seven new completed randomised controlled trials (RCTs) for a total of nine completed RCTs including 1491 participants, addressing four distinct questions about antithrombotic treatment after: intracerebral haemorrhage (ICH): </p> <p> <ul id="CD012144-list-0014"> <li> <p>shortâterm prophylactic dose anticoagulation (start versus avoid);</p> </li> <li> <p>longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid); </p> </li> <li> <p>longâterm antiplatelet therapy (start versus avoid);</p> </li> <li> <p>longâterm antiplatelet therapy (cilostazol versus aspirin).</p> </li> </ul> </p> <section id="CD012144-sec-0071"> <h3 class="title" id="CD012144-sec-0071">Summary of main results</h3> <section id="CD012144-sec-0072"> <h4 class="title">Shortâterm prophylactic dose anticoagulation (start versus avoid)</h4> <p>No RCT reported this review's primary outcome of major adverse cardiovascular events (MACE). The evidence is very uncertain about the effect of starting shortâterm prophylactic dose anticoagulation on death, venous thromboembolism, ICH and independent functional status over 90 days. </p> </section> <section id="CD012144-sec-0073"> <h4 class="title">Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid) </h4> <p>Starting longâterm therapeutic dose oral anticoagulation for atrial fibrillation (AF) after ICH probably reduces MACE (RR 0.61, 95% CI 0.40 to 0.94, P = 0.02; 3 RCTs; moderateâcertainty evidence) and probably reduces all major occlusive events (RR 0.27, 95% CI 0.14 to 0.53, P = 0.0002; 3 RCTs; moderateâcertainty evidence), but probably results in little or no difference in death, probably increases intracranial haemorrhage, and may result in little to no difference in independent functional status.Â  </p> </section> <section id="CD012144-sec-0074"> <h4 class="title">Longâterm antiplatelet therapy (start versus avoid)</h4> <p>The evidence is uncertain about the effects of starting longâterm antiplatelet therapy after ICH on MACE, death, all major occlusive events, ICH, and independent functional status. </p> </section> <section id="CD012144-sec-0075"> <h4 class="title">Longâterm antiplatelet therapy (cilostazol versus aspirin)</h4> <p>For adults within 180 days of nonâcardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior ICH, there was no evidence of an effect of longâterm cilostazol compared to aspirin on MACE, death, or ICH. All major occlusive vascular events and functional status were not reported. </p> </section> </section> <section id="CD012144-sec-0076"> <h3 class="title" id="CD012144-sec-0076">Overall completeness and applicability of evidence</h3> <p>All data were available for RCTs of shortâterm prophylactic dose anticoagulation. The included RCTs were representative of clinical practice in Italy, Germany, Turkey and Finland. </p> <p>Data sufficient for analysis were not provided by the authors ofÂ <a href="./references#CD012144-bbs2-0020" title="OkumuraK , AkaoM , YoshidaT , KawataM , YamashitaT , et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. New England Journal of Medicine2020;383:1735-45. [DOI: 10.1056/NEJMoa2012883]OkumuraK , LipG , AkaoM , TanizawaK , FukuzawaM , AbeK , et al. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: rationale and design of the ELDERCARE-AF study. American Heart Journal2017;194:99-106. [DOI: 10.1016/j.ahj.2017.08.017]">ELDERCAREâAF 2020</a>Â andÂ <a href="./references#CD012144-bbs2-0021" title="OsmancikP , HermanD , NeuzilP , HalaP , TaborskyM , KalaP , et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. Journal of the American College of Cardiology2020;75(25):3122â35. [DOI: 10.1016/j.jacc.2020.04.067]">PRAGUEâ17 2020</a>.Â <a href="./references#CD012144-bbs2-0020" title="OkumuraK , AkaoM , YoshidaT , KawataM , YamashitaT , et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. New England Journal of Medicine2020;383:1735-45. [DOI: 10.1056/NEJMoa2012883]OkumuraK , LipG , AkaoM , TanizawaK , FukuzawaM , AbeK , et al. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: rationale and design of the ELDERCARE-AF study. American Heart Journal2017;194:99-106. [DOI: 10.1016/j.ahj.2017.08.017]">ELDERCAREâAF 2020</a>Â shared the entire trial dataset, but we were unable to extract data on the subgroup of 80 participants with ICH, which would have increased the data in our pooled analyses of the effects of longâterm therapeutic dose oral anticoagulation for AF by 80/334 (24%). The RCTs that were included reflected standard clinical practice in the UK, the Netherlands and Canada. </p> <p>The number of patients with prior ICH inÂ <a href="./references#CD012144-bbs2-0021" title="OsmancikP , HermanD , NeuzilP , HalaP , TaborskyM , KalaP , et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. Journal of the American College of Cardiology2020;75(25):3122â35. [DOI: 10.1016/j.jacc.2020.04.067]">PRAGUEâ17 2020</a>Â was not reported and was not quantified by the corresponding author in communication with us; this RCT would have been the only RCT contributing data to a new comparison of direct oral anticoagulants (DOACs) versus left atrial appendage closure for AF after ICH. </p> <p>Only one RCT addressed longâterm antiplatelet therapy after ICH, and this was based in the UK (<a href="./references#CD012144-bbs2-0008" title="Al-Shahi SalmanR , DennisM , MurrayG , InnesK , DreverJ , DinsmoreL , et al. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. Trials2018;19:162. [DOI: 10.1186/s13063-018-2542-6]Al-Shahi SalmanR , MinksDP , MitraD , RodriguesMA , BhatnagarP , du PlessisJC , RESTART Collaboration. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology2019;18(7):643-52. [DOI: 10.1016/S1474-4422(19)30184-X] [PMID: 31129065]RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet2019;393(10191):2613-23. [DOI: 10.1016/S0140-6736(19)30840-2] [PMID: 31128924]">RESTART 2019</a>). </p> <p>Only one RCT compared different types of antiplatelet therapy after ICH, and this was based in South Korea, Hong Kong, and the Philippines (<a href="./references#CD012144-bbs2-0005" title="KimBJ , KwonSU , ParkJH , KimYJ , HongKS , WongLK , PICASSO Investigators. Cilostazol versus aspirin in ischemic stroke patients with high-risk cerebral hemorrhage: subgroup analysis of the PICASSO Trial. Stroke2020;51(3):931-7. [CLINICALTRIALS.GOV: NCT01013532] [DOI: 10.1161/STROKEAHA.119.023855] [PMID: 31856691]KimBJ , LeeEJ , KwonSU , ParkJH , KimYJ , HongKS , PICASSO investigators. Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. Lancet Neurology2018;17(6):509-18. ">PICASSO subâgroup 2020</a>). </p> </section> <section id="CD012144-sec-0077"> <h3 class="title" id="CD012144-sec-0077">Quality of the evidence</h3> <p>The methodological quality of the included RCTs varied, and tended to be best for the RCTs comparing starting versus avoiding longâterm therapeutic dose oral anticoagulation for AF after ICH and the RCT comparing starting versus avoiding longâterm antiplatelet therapy after ICH.Â  </p> <p>Most RCTs did not blind patients and professionals to treatment allocation, so the body of evidence was most vulnerable to performance bias, although all of our outcomes were objective with the exception of functional status. The proportion of included RCTs at low risk of bias, by category was: random sequence generation (67%), allocation concealment (67%), performance (22%), detection (78%), attrition (89%), and reporting (78%). </p> <p>Heterogeneity between the RCTs' results varied according to the comparisons and outcomes being analysed, but the I<sup>2</sup> was less than 75% for all 15 analyses that pooled at least two RCTs. </p> <p>The risk of bias of the included RCTs and the imprecision of individual or pooled RCTs meant that the GRADE certainty of evidence was very low for RCTs of shortâterm prophylactic dose anticoagulation, low to moderate for RCTs of longâterm therapeutic dose oral anticoagulation for AF, moderate for longâterm antiplatelet therapy and low for longâterm cilostazol versus aspirin. </p> </section> <section id="CD012144-sec-0078"> <h3 class="title" id="CD012144-sec-0078">Potential biases in the review process</h3> <p>We minimised the effects of publication bias by conducting extensive searches for published and unpublished RCTs, reviewing bibliographies for additional RCTs, and by seeking missing data directly from authors. </p> <p>We minimised selection bias by involving two review authors in study selection and data extraction, with arbitration and independent checking by a third review author. </p> <p>We collected data for all outcomes that were reported (and added pulmonary embolism, venous thromboembolism, and various variants of the MACE composite outcome relevant to the assessment of efficacy and net benefit). </p> </section> <section id="CD012144-sec-0079"> <h3 class="title" id="CD012144-sec-0079">Agreements and disagreements with other studies or reviews</h3> <p>We identified two systematic reviews of shortâterm antithrombotic treatment after ICH in RCTs (<a href="./references#CD012144-bbs2-0049" title="KeirSL , WardlawJM , SandercockPA , ChenZ . Antithrombotic therapy in patients with any form of intracranial haemorrhage: a systematic review of the available controlled studies. Cerebrovascular Diseases2002;14(3-4):197-206. [DOI: 10.1159/000065661]">Keir 2002</a>;Â <a href="./references#CD012144-bbs2-0055" title="PaciaroniM , AgnelliG , VentiA , AlbertiA , AcciaressiM , CasoV . Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies. Journal of Thrombosis and Haemostasis2011;9:893-8. [DOI: 10.1111/j.1538-7836.2011.04241.x]">Paciaroni 2011</a>), and a third systematic review of longâterm antiplatelet therapy after ICH (<a href="./references#CD012144-bbs2-0038" title="ChengB , LiJ , PengL , WangY , SunL , HeS , et al. Efficacy and safety of restarting antiplatelet therapy for patients with spontaneous intracranial haemorrhage: a systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics2021;46:957-65. [DOI: 10.1111/jcpt.13377]">Cheng 2021</a>). </p> <p><a href="./references#CD012144-bbs2-0049" title="KeirSL , WardlawJM , SandercockPA , ChenZ . Antithrombotic therapy in patients with any form of intracranial haemorrhage: a systematic review of the available controlled studies. Cerebrovascular Diseases2002;14(3-4):197-206. [DOI: 10.1159/000065661]">Keir 2002</a>Â included individual participant data fromÂ <a href="./references#CD012144-bbs2-0014" title="International Stroke Trial Collaborative Group. The International Stoke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet1997;349(9065):1569-81. [DOI: 10.1016/S0140-6736(97)04011-7] [PMID: 9186381]">IST 1997</a>Â andÂ <a href="./references#CD012144-bbs2-0011" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke; CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet1997;349(9066):1641-9. [DOI: 10.1016/S0140-6736(97)04010-5] [PMID: 9186381]">CAST 1997</a>Â on participants with not only ICH (52%), but also haemorrhagic transformation of cerebral infarction (48%), although it did not describe results for patients with ICH alone, who are the focus of this systematic review. This review's conclusions did not differ from ours. </p> <p><a href="./references#CD012144-bbs2-0055" title="PaciaroniM , AgnelliG , VentiA , AlbertiA , AcciaressiM , CasoV . Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies. Journal of Thrombosis and Haemostasis2011;9:893-8. [DOI: 10.1111/j.1538-7836.2011.04241.x]">Paciaroni 2011</a>Â andÂ <a href="./references#CD012144-bbs2-0038" title="ChengB , LiJ , PengL , WangY , SunL , HeS , et al. Efficacy and safety of restarting antiplatelet therapy for patients with spontaneous intracranial haemorrhage: a systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics2021;46:957-65. [DOI: 10.1111/jcpt.13377]">Cheng 2021</a>Â pooled nonârandomised studies as well as RCTs, which is a less methodologically rigorous approach than pooling RCTs alone. These reviews' conclusions did not differ from ours. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012144-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of study screening, eligibility assessment and inclusion" data-id="CD012144-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of study screening, eligibility assessment and inclusion</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-FIG-02" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012144-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 1: Death" data-id="CD012144-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 1: Death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 2: Deep vein thrombosis" data-id="CD012144-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 2: Deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 3: Pulmonary embolism" data-id="CD012144-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 3: Pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 4: Venous thromboembolism" data-id="CD012144-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 4: Venous thromboembolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 5: Intracerebral haemorrhage" data-id="CD012144-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 5: Intracerebral haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 6: Major extracerebral haemorrhage" data-id="CD012144-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 6: Major extracerebral haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 7: Growth of qualifying intracerebral haemorrhage" data-id="CD012144-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 7: Growth of qualifying intracerebral haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 8: Functional status (modified Rankin Scale 0â2)" data-id="CD012144-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Shortâterm prophylactic dose anticoagulation (start versus avoid), Outcome 8: Functional status (modified Rankin Scale 0â2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 1: All major adverse cardiovascular events (MACE)" data-id="CD012144-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 1: All major adverse cardiovascular events (MACE) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 2: Death" data-id="CD012144-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 2: Death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 3: Ischaemic stroke" data-id="CD012144-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 3: Ischaemic stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 4: Myocardial infarction" data-id="CD012144-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 4: Myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 5: All major occlusive vascular events" data-id="CD012144-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 5: All major occlusive vascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 6: Intracranial haemorrhage" data-id="CD012144-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 6: Intracranial haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 7: Major extracerebral haemorrhage" data-id="CD012144-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 7: Major extracerebral haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 8: Vascular death" data-id="CD012144-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 8: Vascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 9: Functional status (modified Rankin Scale score 0â2) at 1 year" data-id="CD012144-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 9: Functional status (modified Rankin Scale score 0â2) at 1 year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 10: Any stroke (ischaemic or haemorrhagic)" data-id="CD012144-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 10: Any stroke (ischaemic or haemorrhagic) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 11: Any stroke (ischaemic or haemorrhagic) or vascular death" data-id="CD012144-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid), Outcome 11: Any stroke (ischaemic or haemorrhagic) or vascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 1: All major adverse cardiovascular events (MACE)" data-id="CD012144-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 1: All major adverse cardiovascular events (MACE) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 2: Death" data-id="CD012144-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 2: Death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 3: Ischaemic stroke" data-id="CD012144-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 3: Ischaemic stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 4: Myocardial infarction" data-id="CD012144-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 4: Myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 5: All major occlusive vascular events" data-id="CD012144-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 5: All major occlusive vascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 6: Intracerebral haemorrhage" data-id="CD012144-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 6: Intracerebral haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 7: Major extracerebral haemorrhage" data-id="CD012144-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 7: Major extracerebral haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 8: Vascular death" data-id="CD012144-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 8: Vascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 9: Functional status (modified Rankin Scale score 0â2) at 1 year" data-id="CD012144-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 9: Functional status (modified Rankin Scale score 0â2) at 1 year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 10: Deep vein thrombosis" data-id="CD012144-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 10: Deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 11: All major haemorrhagic events" data-id="CD012144-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 11: All major haemorrhagic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 12: Major vascular events as defined by the Antithrombotic Trialistsâ Collaboration" data-id="CD012144-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Longâterm antiplatelet therapy (start versus avoid), Outcome 12: Major vascular events as defined by the Antithrombotic Trialistsâ Collaboration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 1: All major adverse cardiovascular events (MACE)" data-id="CD012144-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 1: All major adverse cardiovascular events (MACE) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 2: Death" data-id="CD012144-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 2: Death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 3: Ischaemic stroke" data-id="CD012144-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 3: Ischaemic stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 4: Myocardial infarction" data-id="CD012144-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 4: Myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 5: Intracerebral haemorrhage" data-id="CD012144-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 5: Intracerebral haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 6: Vascular death" data-id="CD012144-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 6: Vascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012144-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/urn:x-wiley:14651858:media:CD012144:CD012144-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 7: Any stroke (ischaemic or haemorrhagic)" data-id="CD012144-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_t/tCD012144-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Longâterm antiplatelet therapy (cilostazol versus aspirin), Outcome 7: Any stroke (ischaemic or haemorrhagic) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/media/CDSR/CD012144/image_n/nCD012144-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012144-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Summary of findings table â Starting shortâterm prophylactic dose anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Starting shortâterm prophylactic dose anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> survivors of stroke due to intracerebral haemorrhage<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> starting shortâterm prophylactic dose anticoagulation<br/><b>Comparison:</b> avoiding anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with avoiding anticoagulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with starting shortâterm prophylactic dose anticoagulation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MACE â not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death<br/>assessed with: clinical assessment<br/>followâup: 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>175 per 1000</b><br/>(103 to 297) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.59 to 1.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venous thromboembolism<br/>assessed with: clinical assessment<br/>followâup: 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b><br/>(72 to 195) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b><br/>(0.51 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intracerebral haemorrhage (ICH)<br/>assessed with: brain imaging and clinical assessment<br/>followâup: 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><br/>(4 to 143) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.24</b><br/>(0.04 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functional status: mRS 0â2<br/>assessed with: clinical assessment<br/>followâup: 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>290 per 1000</b><br/>(111 to 750) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.03</b><br/>(0.78 to 5.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424458755853554175" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424458755853554175</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The included RCTs have serious risk of bias due to lack of blinding to treatment, and random sequence generation and allocation concealment not being adequately described.<br/><sup>b</sup> The optimal information size (OIS) criterion is not met. The sample size of this study is probably lower than the minimum number of participants required for a trial adequately powered to identify a statistically significant difference for this outcome.<br/><sup>c</sup> Very small pooled sample size<br/><sup>d</sup> Low pooled sample size and event rate<br/><sup>e</sup> Extremely small pooled sample size </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Summary of findings table â Starting shortâterm prophylactic dose anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012144-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Summary of findings table â Starting longâterm therapeutic dose oral anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage with atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Starting longâterm therapeutic dose oral anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage with atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> survivors of stroke due to intracerebral haemorrhage with atrial fibrillation <br/><b>Setting:</b> Secondary care<br/><b>Intervention:</b> starting longâterm therapeutic dose oral anticoagulation<br/><b>Comparison:</b> avoiding anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with avoiding anticoagulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with starting longâterm therapeutic dose oral anticoagulation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MACE (MACE)<br/>assessed with: clinical assessment<br/>followâup: range 1 years to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>158 per 1000</b><br/>(104 to 244) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.61</b><br/>(0.40 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death<br/>assessed with: clinical assessment<br/>followâup: range 1 years to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b><br/>(84 to 242) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/>(0.62 to 1.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All major occlusive vascular events<br/>assessed with: clinical assessment<br/>followâup: range 1 years to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b><br/>(29 to 111) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.27</b><br/>(0.14 to 0.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intracranial haemorrhage<br/>assessed with: clinical assessment<br/>followâup: range 1 years to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b><br/>(27 to 208) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.43</b><br/>(0.88 to 6.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functional status (mRS 0â2)<br/>assessed with: clinical assessment<br/>followâup: 1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>490 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b><br/>(382 to 607) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b><br/>(0.78 to 1.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low<sup>b,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431448658702855854" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431448658702855854</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> All included randomised trials were open label, but these outcomes were objective.<br/><sup>b</sup> These are the results of a small number of events being observed in three RCTs with relatively small sample sizes.<br/><sup>c</sup> The pooled estimate was imprecise due to the small number of outcome events<br/><sup>d</sup> All included randomised trials were open label, and this outcome was subjective </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Summary of findings table â Starting longâterm therapeutic dose oral anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage with atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012144-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Summary of findings table â Starting longâterm oral antiplatelet therapy compared to avoiding antithrombotic therapy for survivors of stroke due to intracerebral haemorrhage</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Starting longâterm oral antiplatelet therapy compared to avoiding antithrombotic therapy for survivors of stroke due to intracerebral haemorrhage</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> survivors of stroke due to intracerebral haemorrhage<br/><b>Setting:</b> Secondary care<br/><b>Intervention:</b> starting longâterm oral antiplatelet therapy<br/><b>Comparison:</b> avoiding antithrombotic therapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with avoiding antithrombotic therapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with starting longâterm oral antiplatelet therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MACE<br/>assessed with: clinical assessment<br/>followâup: median 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>228 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>203 per 1000</b><br/>(146 to 278) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b><br/>(0.64 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death<br/>assessed with: clinical assessment<br/>followâup: median 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b><br/>(142 to 285) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b><br/>(0.76 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All major occlusive vascular events<br/>assessed with: clinical assessment<br/>followâup: median 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b><br/>(96 to 220) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b><br/>(0.68 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intracerebral haemorrhage (ICH)<br/>assessed with: clinical assessment<br/>followâup: median 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b><br/>(23 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.52</b><br/>(0.27 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fnctional status (mRS 0â2)<br/>assessed with: clinical assessment<br/>followâup: 1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>433 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>411 per 1000</b><br/>(333 to 511) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/>(0.77 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>461<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431448890153987933" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431448890153987933</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The included randomised trial was open label but outcomes were objective.<br/><sup>b</sup> Only one randomised trial with 537 participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Summary of findings table â Starting longâterm oral antiplatelet therapy compared to avoiding antithrombotic therapy for survivors of stroke due to intracerebral haemorrhage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012144-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span>Â <span class="table-title">Summary of findings table â Cilostazol compared to aspirin for adults within 180 days of nonâcardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral haemorrhage</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cilostazol compared to aspirin for adults within 180 days of nonâcardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral haemorrhage</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults within 180 days of nonâcardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral haemorrhage<br/><b>Setting:</b> Secondary care<br/><b>Intervention:</b> cilostazol<br/><b>Comparison:</b> aspirin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with aspirin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with cilostazol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MACE<br/>assessed with: clinical assessment<br/>followâup: median 1.8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>116 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>155 per 1000</b><br/>(86 to 279) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b><br/>(0.74 to 2.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death<br/>assessed with: clinical assessment<br/>followâup: median 1.8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b><br/>(19 to 168) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.65</b><br/>(0.55 to 4.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All major occlusive vascular events â not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intracerebral haemorrhage (ICH)<br/>assessed with: clinical assessment<br/>followâup: median 1.8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b><br/>(10 to 128) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b><br/>(0.35 to 4.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functional status â not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431449016706363235" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431449016706363235</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The report of the subâgroup of the PICASSO trial did not report major extracerebral haemorrhage, DVT or functional status.<br/><sup>b</sup> Small sample size from a subâgroup of the PICASSO trial </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span>Â <span class="table-title">Summary of findings table â Cilostazol compared to aspirin for adults within 180 days of nonâcardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral haemorrhage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012144-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span>Â <span class="table-title">Nonâenzymatic antithrombotic agents with defined daily doses within group B01A of the World Health Organization Anatomical Therapeutic Chemical Classification System</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Antithrombotic class</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Antithrombotic agents</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vitamin K antagonists</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dicoumarol, phenindione, warfarin, phenprocoumon, acenocoumarol, ethyl biscoumacetate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heparin group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heparin, antithrombin III, dalteparin, enoxaparin, nadroparin, parnaparin, reviparin, danaparoid, tinzaparin, sulodexide, bemiparin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Platelet aggregation inhibitors excluding heparin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clopidogrel, ticlopidine, acetylsalicylic acid, dipyridamole, carbasalate calcium, epoprostenol, indobufen, iloprost, abciximab, aloxiprin, eptifibatide, tirofiban, triflusal, beraprost, treprostinil, prasugrel, cilostazol, ticagrelor, cangrelor, vorapaxar, selexipag </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Direct thrombin inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Desirudin, lepirudin, argatroban, melagatran, ximelagatran, bivalirudin, dabigatran etexilate* </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Direct factor Xa inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rivaroxaban*, apixaban*, edoxaban*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other antithrombotic agents</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defibrotide, fondaparinux</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p><a href="https://www.whocc.no/atc_ddd_index/?code=B01A" target="_blank">www.whocc.no/atc_ddd_index/?code=B01A</a> </p> <p>* Nonâvitamin K (direct) oral anticoagulants</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span>Â <span class="table-title">Nonâenzymatic antithrombotic agents with defined daily doses within group B01A of the World Health Organization Anatomical Therapeutic Chemical Classification System</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/full#CD012144-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012144-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Shortâterm prophylactic dose anticoagulation (start versus avoid)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.59, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.49, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.22, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.51, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Intracerebral haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.04, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Major extracerebral haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [0.12, 65.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Growth of qualifying intracerebral haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.38, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Functional status (modified Rankin Scale 0â2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [0.78, 5.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Shortâterm prophylactic dose anticoagulation (start versus avoid)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012144-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span>Â <span class="table-title">Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All major adverse cardiovascular events (MACE) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.40, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.62, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Ischaemic stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.17, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.02, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 All major occlusive vascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.14, 0.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Intracranial haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [0.88, 6.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Major extracerebral haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.13, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Vascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.65, 3.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Functional status (modified Rankin Scale score 0â2) at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.78, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Any stroke (ischaemic or haemorrhagic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.42, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Any stroke (ischaemic or haemorrhagic) or vascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.46, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span>Â <span class="table-title">Longâterm therapeutic dose oral anticoagulation for atrial fibrillation (start versus avoid)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012144-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span>Â <span class="table-title">Longâterm antiplatelet therapy (start versus avoid)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 All major adverse cardiovascular events (MACE) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.64, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.76, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Ischaemic stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.40, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.21, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 All major occlusive vascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.68, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Intracerebral haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.27, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Major extracerebral haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [0.72, 9.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Vascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.38, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Functional status (modified Rankin Scale score 0â2) at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.77, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.61, 14.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 All major haemorrhagic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.40, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Major vascular events as defined by the Antithrombotic Trialistsâ Collaboration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.49, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span>Â <span class="table-title">Longâterm antiplatelet therapy (start versus avoid)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012144-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span>Â <span class="table-title">Longâterm antiplatelet therapy (cilostazol versus aspirin)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 All major adverse cardiovascular events (MACE) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.74, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.55, 4.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Ischaemic stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.45, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.31 [0.63, 202.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Intracerebral haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.35, 4.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Vascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.35 [0.38, 143.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Any stroke (ischaemic or haemorrhagic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.51, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span>Â <span class="table-title">Longâterm antiplatelet therapy (cilostazol versus aspirin)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012144.pub3/references#CD012144-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012144.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012144-note-0021">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="fa#CD012144-note-0017">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="fr#CD012144-note-0018">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="hr#CD012144-note-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD012144-note-0016">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD012144-note-0014">æ¥æ¬èª</a> </li> <li class="section-language"> <a class="" href="ko#CD012144-note-0011">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="ms#CD012144-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012144-note-0019">Polski</a> </li> <li class="section-language"> <a class="" href="ro#CD012144-note-0020">RomÃ¢nÄ</a> </li> <li class="section-language"> <a class="" href="th#CD012144-note-0012">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012144-note-0010">ç¹é«ä¸­æ</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright Â© 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">Â Â Facebook</a> <a class="a2a_button_x share-button">Â Â X(Twitter)</a> <a class="a2a_button_whatsapp share-button">Â Â WhatsApp</a> <a class="a2a_dd share-button">Â Â View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012144\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012144\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012144\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012144\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012144\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012144.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012144.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">EspaÃ±ol</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">ÙØ§Ø±Ø³Û</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">FranÃ§ais</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">à¤¹à¤¿à¤¨à¥à¤¦à¥</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">æ¥æ¬èª</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">íêµ­ì´</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">PortuguÃªs</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Ð ÑÑÑÐºÐ¸Ð¹</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">RomÃ¢nÄ</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">à®¤à®®à®¿à®´à¯</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">ç¹é«ä¸­æ</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">ç®ä½ä¸­æ</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012144.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012144.pub3/full/es">EspaÃ±ol</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012144.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716388881"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012144.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716388885"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012144.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9e4e6a5a9368',t:'MTc0MDcxNjM4OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 